2025 HFA临床共识声明：心房心肌病—从健康心房到心房衰竭

共识心血管内科· 心力衰竭 · 2025

Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC

Jeremy Weerts ${}^{1,2\dagger}$ , Otilia Tica ${}^{3,4\dagger}$ , Julia Aranyo ${}^{2}$ , Christian Basile ${}^{5,6}$ ,Angelina Borizanova-Petkova ${}^{7,8}$ , Josip Andjelo Borovac ${}^{9}$ , Massimiliano Camilli ${}^{10,11}$ ,Martin Eichenlaub ${}^{12}$ , Emiliano Fiori ${}^{13}$ , Tim Van Loon ${}^{14}$ , Coenraad Withaar ${}^{15}$ ,Diana Zakarkaité ${}^{16}$ , Matthias D. Zink1 ${}^{17}$ , Marianna Adamo ${}^{18}$ , Alberto Aimo ${}^{19}$ ,Elena Arbelo ${}^{20,21,22}$ , Felipe Bisal Van Bylen ${}^{2,22}$ , Dimitrios T. Farmakis ${}^{23}$ ,Dobromir Dobrev ${}^{24,25,26}$ , Jelena Celutkiene ${}^{27,28}$ , Michael Bohm ${}^{29,30}$ ,Andrew Coats ${}^{31}$ , Marco Metra ${}^{18}$ , Giuseppe Rosano ${}^{32,33}$ , Frank Ruschitzka ${}^{34}$ ,Antoni Bayes-Genis ${}^{2}$ , and Dipak Kotecha ${}^{3,35,36}$

1Department of Cardiology,Cardiovascular Research Institute Maastricht, Maastricht, University Medical Centre,Maastricht,The Netherlands;2Heart Institute,Germans Trias Pujol University Hospital, Badalona, Spain; 3Department of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; 4Emergency County Clinical Hospital of Bior,Oradea, Romania; 5Department of Advanced Biomedical Sciences, University of Naples' Federico II', Naples, Italy; 6Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 7Department of Emergency Medicine, Medical University Sofia, Ofafia, Bulgaria; 8Cardiology Clinic, UMHAT'Tsarits Yaanna-ISUL', Sofia, Bulgaria;9Cardiovascular Diseases Department, University Hospital of Split(KBC Split),Split, Croastia; 10Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy; 11Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy; 12Department of Cardiology and Angiology, Medical Center, University of Freiburg, Bad Krozingen, Germany; 13Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy;14Department of Biomedical Engineering, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht,The Netherlands; 15 Department of Cardiology,University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 16Clinic and Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University,Vilnius, Lithuania, 17 Ortenau-Klinkium Lahr, Academic Teaching Hospital University of Freiburg, Lahr, Germany; 18 Cardiology Unit, ASST Spedali Civil di Brescia, Department of Medical and Surgical Specialies, Radiological Sciences, and Public Health, University of Brescia, brescia; Italy; 19 Cardiology Division, Fondazione Toscana Gabriele Monasterio,Health Sciences Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy; 20Arrhythmia Section, Cardiology Department, Hospital Clinic, Universitat de Barcelona,Barcelona, Spain; 21Institut d'Investigaciogic August Pi is Sunyer, Barcelona, Spain; 22Centro de Investigacion Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain;23Heart Failure Unit, Department of Cardiology, Athens University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece; 24Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Germany; 25Department of Integrative Physiology, Baylor College of Medicine, Houston,TX, USA;26 Department of Medicine, Montreal Heart Institute and Universite de Montreal, QC, Canada; 27Centre de Innovative Medicine, Vilnius, Lithuania;28 Universitsklinikum des Saarlands, Klink fur innere Medizin III, Saarland University, Homburg, Germany; 29Kardiologie, Angiologie und Internatische Intensivmedizin,Homburg, Germany; 30Heart Research Institute, Sydney, NSW, Australia; 31C Cardiovascular, St George's University Hospital, London; UK; 32Department of Human Sciences and Promotion of Quality of Life, San Raffaele University of Rome, Italy; 33IRCCS, San Raffaele, Roma; 10 Center for Translational and Experimental Cardiology,Department of Cardiology, University Hospital Zurich, University of Zurich, Switzerland, 35Julius Center, University Medical Center Utrecht, The Netherlands; and 36 Birmingham NHIR Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Received 25 March 2025; revised 20 June 2025; accepted 2 July 2025

J. Weerts et al.

The importance of atrial cardiomyopathy(AtCM) as a specific clinical entity is increasingly recognized. Past definitions have varied, and the lack of consistent cut-offs for imaging parameters and biomarkers have limited clinical utility to diagnose and track AtCM progression.While research has mainly focused on AtCM in the context of atrial fibrillation, emerging evidence underscores its relevance in remodelling and development of heart failure. The aim of this consensus document was to provide a contemporary framework for AtCM, evolve the definitions of AtCM and atrial failure for more widespread clinical use, and help to direct emerging research and future clinical trials.Supporting the work of early career researchers, this consensus document evaluates diagnostic markers and summarizes the underpinning mechanisms, clinical characteristics and prognostic impact of AtCM. Our objective was to bring together new translational scientific progress,catalyse future research and enable clinical application to facilitate better management, for example in patient groups where aggressive control of risk factors or comorbidities could prevent AtCM progression. We redefined AtCM as a graded disorder that includes electrical dysfunction of the atria along with evidence of either mechanical atrial dysfunction, atrial enlargement and/or atrial fibrosis. Atrial failure is the end-stage manifestation of AtCM, characterized by progressive structural, electrophysiological and functional changes. Earlier identification,risk stratification and ongoing research into therapeutic options have the potential to prevent the clinical consequences of AtCM and atrial failure, including adverse patient outcomes and poor quality of life associated with atrial fibrillation and heart failure.

Graphical Abstract

![Quality of life\nAtCM - atrial cardiomyopathy\nElectrical atrial dysfunction\nAND\nMechanical atrial dysfunction\nOR\nAtrial enlargement\nOR\nExcessive atrial fibrosis\nIndexed left atrial volume\n40 mL/m2\nEffective failure\nHospitalisation, thrombo-embolism\nLife expectancy\n](2/aj0YEe4oUhYkBdfpda0fYP/figureb4e1d356388546f7bf6cd5d27edf09e7_0_4.png) The diagnosis of atrial cardiomyopathy(AtCM) requires electrical atrial dysfunction, with evidence of either mechanical atrial dysfunction, atrial enlargement, or excessive atrial fibrosis.The diagnostic cut-points presented are for standard electrocardiogram studies(see Figure 1 for further detail). ECG, electrocardiography.

Keywords

Atrial cardiomyopathy

Introduction

The atria play a significant role in overall cardiac function, as well as systemic and pulmonary haemodynamics.1 Beyond their impact on ventricular filling, they serve as volumetric reservoirs supporting effective ventricular contraction, and house pacemaker cells and other crucial components of the cardiac conduction sys-tem. Moreover, they secrete natriuretic peptides, which are piv-otal in regulating fluid homeostasis and vascular tone. Notably, the atrial myocardium is susceptible to various cardiac and non-cardiac diseases and is particularly sensitive to loading conditions and extra-cardiac factors.

There is a growing realization of the importance of atrial dis-ease, of which the most evident consequences are heart failure

(HF), a syndrome where cardiac function is insufficient for the individual's needs,2,3 and atrial fibrillation(AF), characterized by uncoordinated electrical activation that impedes atrial contrac-tion.4 AF is the most common sustained arrhythmia,5 and increases the risk of stroke and other thromboembolic outcomes, HF and mortality.6,7 The lack of direct correlation in many studies between episodes of AF and subsequent thromboembolism is indicative that AF can be an intermittent manifestation of underlying cardiomyopa-thy.8,9 For example, in patients with continuous pacemaker mon-itoring, subclinical AF>6min is detected in only 15% of patients during the month before an embolic event.10 Rather than wait-ing for incident AF or HF to occur, earlier identification of atrial remodelling may provide an opportunity to intercede. Left atrial(LA) reservoir strain(LASr) is more closely associated with stroke

ESC/HFA consensus statement on atrial cardiomyopathy

and dementia risk than AF,11,12 and in patients with HF and pre-served ejection fraction(HFpEF), mechanical atrial dysfunction is an independent and better predictor than AF to stratify for adverse clinical outcomes.13 There may also be treatment implications;for example, in patients with an embolic stroke of undetermined source, rivaroxaban in the NAVIGATE-ESUS trial had no overall advantage over aspirin in reducing the recurrence of stroke or sys-temic embolism,14 except in patients with an LA diameter exceed-ing 46 mm.15

The term atrial cardiomyopathy(AtCM) was initially proposed in 1972 to describe patients with first-degree heart block and ectopic supraventricular rhythms progressing to persistent atrial standstill.16 Subsequent definitions and consensus documents have moved the field forward scientifically, initially based on correlated histological changes to provide a solid framework for AtCM diagno-sis.17,18 Whilst there are genetic variants proposed in the pathology of AtCM in rare patients,19 genetic predisposition in the majority of those with AtCM is complex and multifactorial, with polygenic risk markers associated with both structural and functional LA param-eters.20,1 The common soil hypothesis22 suggests that stressors such as ageing, cardio-metabolic risk factors and concomitant dis-eases promote(sub)clinical trial disease through mechanisms such as inflammation, endothelial and microvascular dysfunction, fibro-sis, hypercoagulability, and atrial stretch. Underlying atrial disease therefore becomes a specific clinical entity and a potentially tar-getable indicator of adverse prognosis, even in the absence of clinically-detected AF or HF.

The primary aim of the present consensus document was to propose a definition of AtCM that could be applied with ease in clinical practice, and be a scaffold for emerging research that could inform the development of this field(Graphical Abstract). This docu-ment evolves prior definitions, reflects the current state-of-the-art in clinical research, and was designed to be applied not just by elec-trophysiology or HF specialists, but earlier and more widely across different medical specialties. The approach was developed follow-ing a number of in-person and virtual meetings coordinated by the Committee on Atrial Disorders from the Heart Failure Association(HFA) of the European Society of Cardiology(ESC). This included early career investigators involved in basic, translational or clinical research on the mechanisms or clinical manifestations of AtCM.These early career researchers performed and presented reviews of the available literature within each section to inform the con-sensus approach. Our objective was to stimulate this new field within cardiology, underpinning research and clinical trials that can improve patient care and prevent the development of AF, HF and other adverse outcomes.

# Proposed definition of atrial cardiomyopathy and atrial failure

In light of the presently available body of evidence, we propose defining AtCM as'electical and mechanical dysfunction of the atria,resulting from underlying pathological changes that lead to atrial enlarge-ment or atrial fibrosis, with the potential to produce clinical conse-quences.

Consensus was built on the need for both clinical simplicity and also to ensure specificity for AtCM. Hence the diagnosis of AtCM requires demonstration of electrical atrial dysfunction in combination with evidence of either mechanical atrial dysfunction, atrial enlarge-ment and/or excessive atrial fibrosis(Figure 1). Combining markers in this way may also avoid over-diagnosis, particularly as a variety of diseases can cause similar features of atrial disruption. The pos-sible manifestations of electrical and mechanical atrial dysfunction are discussed below. Further, we comment on the cut-offs for atrial enlargement, emerging methods to detect atrial fibrosis, biomark-ers that could in future help to refine risk and diagnosis of AtCM,and the molecular underpinning of AtCM that could reveal future targets for therapeutic intervention.

Atrial cardiomyopathy can be due to primary atrial disease without other relevant initial cardiac abnormalities, or secondary to existing ventricular and/or valvular disease. Similar to ventricular myopathy, AtCM has a spectrum of severity and the combination of different atrial disease markers will likely indicate a higher risk of progression. AtCM can manifest through abnormalities in atrial geometry, wall structure and function, which are typically detected by cardiac imaging techniques. However, the severity and consistency of these abnormalities lack universally accepted,and prognostically documented cut-offs. Furthermore, reference values are only available for a limited number of atrial markers.23,24 Underpinning this iterative proposed AtCM framework is the ability for surrogate biomarkers to allow for earlier and more accurate detection of AtCM. Most of the atrial markers studied have shown association with risk of stroke and thromboembolism even in the absence of AF, including LA size25 and advanced inter-atrial block(IAB).23,26 However, there is clear need for more research to identify the most reproducible and easily applicable markers for routine clinical practice.

More pragmatic and hence earlier diagnosis of AtCM has the potential to prevent atrial failure, the end-stage of AtCM manifes-tation occurring due to progressive structural, electrophysiological and functional changes.27 Atrial failure is characterized by clinical manifestations such as persistent AF or documented HF, with dys-pronea, fatigue and impaired quality of life attributable(at least in part) to atrial disease. A combination of the proposed AtCM mark-ers presumably leads to a higher risk of atrial failure. This presents an opportunity for timely risk stratification and management in patients with AtCM, or those at risk of AtCM, to prevent or delay atrial failure. Pending future clinical trials in AtCM, at present this could include aggressive management of underlying risk factors and comorbidities.

Future directions

Clinical validation studies of the proposed AtCM definition frame-work will be required, along with iterative updates over time to reflect new research findings, new technology, and changing patient substrate and comoridity patterns. There is limited evidence cur-rently on the role of natriuretic peptides and other biomarkers to stratify risk of AtCM and atrial failure. Well-powered studies are essential to develop approaches that have diagnostic accuracy for AtCM and can be easily implemented in routine practice. It is likely

J. Weerts et al.

![Healthy atria\nAt-risk of AtCM\not\npotential window of opportunity to prevent AtCM and atrial failure\nProlonged p-wave duration(≥120ms standard,≥150ms amplified)'\nAutomatic rhythmia\nMechanical atrial dysfunction\nAtrial enlargement\nAtrial enlargement dysfunction\nAtrial enlargement fibrosis\nPerioding p-wave duration(≥120ms standard,≥150ms amplified)'\nPersistent atrial arrhythmia\nMechanical atrial dysfunction\nAtrial enlargement dysfunction\nAtrial enlargement fibrosis\nAPorted ng-wave duration(≥120ms standard,≥150ms amplified)'\nPersistent Arrial arrhythmia\nAPorted ng-wave fraction(≥150ms modified)'\nMechanical atrial dysfunction\nAPorted ngaveonral arrhythmia\nAPorted ngaveonral arrhythmia\nAPorted ngaveonral arrhythmia\nAPorted ngaveonral arrhythmia\nAPorted ngaveonral arrhythmia\nAPorted ngaveonral arrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarrhythmia\nAPorted ngaveonralarr yang's disease; and counselling against sedentary habit, obesity, smoking and alcohol abuse. ${}^{2,3}$ \nPotential therapeutic interventions\naggressive management of risk factors $\mathcal{B}$ comorbidities\n? prevent or delay ATPM development\ncontrolicIPM development\ncontrolicIPM\nslow progression of AF& HF\nof AF& HF\n](2/aj0YEe4oUhYkBdfpda0fYP/figuredac0b8e86abb4173b6e819b053d443ec_0_2.png) Figure 1 Consensus approach to diagnosis of atrial cardiomyopathy(AtCM) and prevention of atrial failure. AtCM is defined as electrical and mechanical dysfunction of the atria, resulting from underlying pathological changes that lead to atrial enlargement or atrial fibrosis, with the potential to produce clinical consequences. The diagnostic cut-points for AtCM in this document will need to be updated with new studies; although somewhat arbitrary, they represent the consensus group's best approximation of a workable AtCM diagnosis at this time. 2D,two-dimensional; AF atrial fibrillation; CMR, cardiac magnetic resonance; CVD, cardiovascular disease; ESC, European Society of Cardiology; HF,heart failure; IAB, inter-atrial block. ${}^{3}$ Numbers in circles represent the AtCM P-wave score; see Table 2 for other relevant P-wave abnormalities.bFor women aged>65 years, the 2D-echo AtCM threshold for indexed left atrial volume is>48 mL/m2.°Clinical trials are needed specifically in patients at risk or with AtCM. The 2024 ESC guidelines on AF have class I recommendations on primary prevention of AF for maintaining optimal blood pressure, normal weight and an active lifestyle, and avoidance of binge drinking. ${}^{4}$ The 2021/2023 ESC guidelines on HF have class I recommendations on primary prevention of HF for treatment of hypertension; statins in those at high risk of CVD; sodium-glucose co-transporter 2 inhibitors in patients with diabetes and CVD, or diabetes and chronic kidney disease; finerenone in patients with diabetes and chronic kidney disease; and counselling against sedentary habit, obesity, smoking and alcohol abuse.2,3

that additional manifestations of atrial failure remain undiscovered and warrant further exploration. Robust studies are needed that can inform on strategies to prevent progression of AtCM to atrial failure.

Diagnostic criteria for electrical atrial dysfunction

Surface electrocardiography(ECG) is a widely available technique to assess cardiac electrophysiology in humans. The ECG has been the hallmark of AF diagnosis.28 The ECG can also be used to predict future incidence of AF or HF,29,30 with ECGs displaying distinct features once atrial dysfunction develops(Figure 2). The presence of paroxysmal AF is an opportunity to interced in the progression of AtCM at a‘pre-atrial failure’ stage, but many of these ECG markers occur even earlier, allowing for pre-emptive action to address the underlying drivers of AtCM.

P-wave abnormalities in atrial cardiomyopathy

Under normal conditions, the sinatrial impulse propagates from the right to the left atrium predominantly through the Bachmann

bundle, allowing fast and synchronic biauricular depolarization. ${}^{31}$ A normal P-wave has duration<110ms, is positive in inferior leads, with a biphasic morphology only in V1. Additionally, the normal P-wave usually has a voltage>0.1mV and an axis between 0 and 75°. Any alteration in electrophysiological properties, atrial structure or atrial function are typically reflected by changes in P-wave morphology, highlighting the importance of P-wave analysis to indicate AtCM.

Several P-wave abnormalities have been reported.31,32 One of the most studied parameters is the presence of IAB, caused by a conduction delay or Bachmann's bundle block.33 In this context,the depolarization of the left atrium occurs caudo-cranially via sep-tal and coronary sinus fibers, causing significant electromechanical asynchrony. IAB is defined as a P-wave duration≥120ms and is classified into three degrees: partial(P-wave duration>120 ms with positive polarity and usually bimodal morphology in the inferior leads); advanced(P-wave duration≥120ms with Bachmann's bun-dle block showing biphasic configuration in≥2 inferior leads due to caudo-cranial depolarization); and intermittent(when a variable degree of block appears).34 The diagnosis of IAB is frequently asso-ciated with LA remodelling and fibrosis. IAB, especially advanced IAB, has been associated with an increased risk for adverse out-comes, such as AF, ischaemic stroke, cognitive impairment, HF

ESC/HFA consensus statement on atrial cardiomyopathy

![ATRIAL ENLARGEMENT\nP-WAVE ABNORMALITIES\n0.12 s\n0.12 s\nP-wave duration Interatrial block\nSTROKE\nATRIAL DYSFUNCTION\nAmplified P-wave duration\n0.15 s\nATRIAL FIBROSIS\nAbnormal Voltage\nTerminal force V1\nVASCULAR DEMENTIA\nHEART FAILURE\nATRIAL FIBROSIS\nAbnormal spatial axis\nDYSSYNCHRONY\nAbnormal dispersion\nDEATH\nDYSSYNCHRONY\n](2/aj0YEe4oUhYkBdfpda0fYP/figure2d9f553340a64e25b6a39c9aed52e85b_0_2.png) Figure 2 Electrocardiographic markers indicating atrial disorders. Visual summary of P-wave abnormalities measured on an electrocardio-gram. Most P-wave abnormalities have been associated with imaging modalities of atrial cardiomyopathy, as well as cardiovascular adverse events.

and mortality. ${}^{23,35-38}$ The association between IAB and new-onset supraventricular arrhythmias, including AF, is known as Bayes syn-drome.39 The risk of AF has been reported to increase twofold and fourfold in patients with partial and advanced IAB, respectively. ${}^{40}$

Although the majority of evidence comes from advanced IAB,other P-wave indexes have also been linked with AtCM. Further-more, IAB is typically associated with an advanced AtCM stage and may be absent in patients with a diffuse or patchy disease sub-strate.41 Therefore, it is important to combine IAB assessment with other sensitive ECG parameters to evaluate earlier stages of AtCM. Measurement of the P-wave duration allows the quantifica-tion of interatrial conduction slowing in patients with AtCM and is also associated with ischaemic stroke, cognitive impairment, HF and mortality. ${}^{42,43}$ However, the reported cut-off values for vari-ous clinical outcomes are highly variable. In a large cohort study,both a very short and a very long P-wave duration were associ-ated with the occurrence of death, stroke and AF.44 This might be explained by patients with advanced AtCM having hidden or under-estimated P-wave prolongation, as low-amplitude P-wave compo-nents may not be visualized on the 12-lead ECG using standard settings. ${}^{41,43}$ Amplification of the 12-lead ECG might be useful to appreciate low-amplitude components, allowing for measurement of the amplified P-wave duration that is highly correlated with LA hypertension, mechanical dysfunction, and invasively-measured low-voltage areas. ${}^{45}$ Other techniques that enhance ECG analysis and aid AtCM detection include additional leads and higher sample rates for advanced post-processing analysis. ${}^{46-51}$

Additional P-wave indexes, such as voltage, axis, morphology,dispersion, area, and terminal force in V1, have also been described as risk factors for AF, stroke,HF, dementia and mortality.52-54 Each ECG parameter has advantages and disadvantages in determining AtCM(Table 1). Besides these‘classical’ ECG parameters, artificial intelligence has the potential to significantly improve AtCM diag-nosis, as demonstrated for new-onset AF, HF, and mortality.

P-wave characteristics to diagnose atrial cardiomyopathy

P-wave abnormalities may identify a subset of patients with pre-viously undetected AtCM, allowing for risk stratification and the potential for specific preventive or therapeutic measures. We pro-pose a score based on the P-wave, where the parameters with the most evidence provide the most weight(Table 2). Explana-tion on how to perform P-wave measurements is elaborated in Appendix 1 and Figure 3. Intermediate risk(score of 1 or 2) is represented by patients with prolonged P-wave duration or IAB,but without clinical atrial arrhythmias. The management of these earlier stages of AtCM(preceding clinical AF) remains an area of relative knowledge gap, 56-58 although it may be possible to prevent or delay AtCM progression and inhibit progression to atrial fail-ure. The use of anticoagulants and rhythm control strategies in this group remains controversial and requires further investigation. It is conceivable that diligent comorbidity and risk factor management of patients with intermediate risk may slow down atrymodelling

J. Weerts et al.

Table 1 Strengths and weaknesses of P-wave parameters to predict atrial cardiomyopathy

|P-wave parameter|Strength|Weakness| |---|---|---| |IAB|Evidence+++ for advanced IAB in advanced AtCM stages Easy to measure|Less evidence for partial IAB Moderate sensitivity| |P-wave duration|Evidence ++ for early AtCM stages Easy to measure|Undersensing of low-amplitude P-wave components using standard settings Signal-to-noise ratio No established pathological cut-off Undersensing of low-amplitude P-wave| |P-wave voltage|Evidence Easy to measure|Underersensing of low-amplitude P-wave| |P-wave axis|Easy to measure|components using standard settings Signal-to-noise ratio| |P-wave terminal force V1|Evidence ++ Easy to measure|Components using standard IAB Difficult to measure| |P-wave dispersion|Evidence|Long recording ECG Difficult to measure| |P-wave area|Easy to measure|Little evidence Difficult to measure| |P-wave morphology in orthogonal leads|Evidence|Difficult to measure|

AtCM,atrial cardiomyopathy;ECG,electrocardiography;IAB,inter-atrial block.

Table 2 Atrial cardiomyopathy P-wave score

|P-wave disturbances to identify|Score| |---|---| |electrical arterial dysfunction and AtCM risk|| |Absence of any changes in P-wave parameters|0| |Prolonged P-wave duration(≥120ms on|1| |standard ECG or≥150ms on amplified|| |12-lead ECG)|| |Advanced inter-atrial block(P-wave≥120ms|2| |plus biphasic morphology in≥2 inferior|| |leads) without clinical atrial arrhythmia|| |Advanced inter-atrial block with episodes of|3| |paroxysmal atrial arrhythmia|| |Persistent atrial arrhythmia|4| |The diagnosis of AtCM according to this consensus approach requires docu- mented electrical atrial dysfunction (AtCM P-wave score of 1 or more) in com- bination with evidence of either mechanical atrial dysfunction, atrial enlargement, or excessive atrial fibrosis. Patients at risk of AtCM P(score of 1 or deserve proactive management of comorbidity and risk factors to prevent or revert pro- gression of structural and mechanical dysfunction. A total score of 3 or more||

and subsequently prevent the onset of AF and/or HF.59 A score of≥3 is obtained in the presence of paroxysmal or persistent AF, high-lighting the need for anticoagulation or antiarthmionic strategies to effectively manage the condition. In the presence of persistent AF,

the 12-lead ECG becomes less useful, and prognostic stratification tools become more relevant. These include, for example, continu-ous monitoring to determine AF burden or ventricular response. ${}^{60}$ Patients with AF but without demonstrable AtCM are of special interest to deepen the understanding of the AtCM framework,including AF due to specific triggers such as critical illness, alcohol intake and genetic background.

Future directions

Improved ability to distinguish anatomical versus functional fac-tors underpinning specific P-wave disorders would help to rede fine ECG-based risk prediction of AtCM. The appropriate ablation strategy in patients with AF61 and advanced atrial failure, and its ability to modify the substrate and progression of the disease,requires further investigation. In addition, clarification is needed on the role of invasive techniques, such as atrial high-density electro-anatomical mapping, to diagnose AtCM and for prognostic stratification. Artificial intelligence algorithms are being developed to automate P-wave analysis,62 and could play an increasing role in future clinical practice once reliability, accuracy and diagnos-tic/prognostic prediction are clarified.

Diagnostic criteria for mechanical atrial dysfunction

Atrial remodelling occurs in parallel with electrical dysfunction and leads to persistent changes in atrial size and function, often associated with increased susceptibility to atrial arrhythmias. ${}^{63}$

ESC/HFA consensus statement on atrial cardiomyopathy

![A: Duration of p-wave\nFILTERING\n2a\np-wave\nduration\nOffset\nOffset\np-wave\n3a\nOnset\nOffset\nonset\nArtefactos and small electrical\ncardiac activity disappears\n3\n3b\nOffset\nOffset\np-wave\nduration\nArtefactos disappear while electrical\nOffset\nactivity at the end of the p-wave\nB: Left atrial strain\n1\n2a\n×\n3c\n×\n3c\nExtrapolate: LA appendageo Orfices of pulmonary veins\nusing a pulse voltage\nusing a pulse voltage\n2\n\n3c\n×\n3c\n×\n3c\n&\n4c\n5c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\n×\n3c\nForbected: Quality of semi-automatic contouring\nLeft atrium in apical 4-chamber view: contouring of left atrial borders for speckle tracking\n3\n4\n](2/aj0YEe4oUhYkBdfpda0fYP/figure6113f8beb4434b0697f8f2955fa0fedc_0_2.png) ![B: Left atrial strain\n3\nExtrapol: 20 LA appendage 01 orices of pulmonary veins\nChecking for quality of semi-automatic contouring\nLeft atrial in apical 4-chamber\nview: contouring of left atrial borders for speckle tracking\n3 phases of LA strain: (R) Reservoir, (C) Conduit, (B) Booster\n](2/aj0YEe4oUhYkBdfpda0fYP/figure90b8dc2d9a284e6d9e050e413044982f_0_3.png) Figure 3 Electrocardiogram(ECG) and imaging evaluation for atrial cardiomyopathy.(A) Steps for calculating P-wave duration(see Appendix 1 for details). Step 1: an unfiltered P-wave in V1 shows small changes in electrical activity(arrows) which can be a result of small artefacts(electrical noise, muscle activity, or others). Step 2a: by applying routine filters for a standard ECG recording, the macro-shape of the P-wave atrial electrical activity and low amplitudes may be neglected in marking in atrial electrical activity. Step 3a: parts of the P-wave with small P-wave consists of a long recording of unfiltered ECG(light grey lines). By calculating the average P-wave signal(black line) of these unfiltered ECGs, randomly distributed artefacts disappear while small changes in atrial electrical activity are preserved. Step 3b: this allows exact marking of the earliest and last atrial electrical activity.(B) Steps for calculating left atrial(LA) strain(see Appendix 2 for details). LA reservoir strain: filling. The obtained value is always positive. LA conduit strain: the second positive peak following the P-wave in the pre-contraction phase.In sinus rhythm, this phase occurs from the time of mitral valve opening through diastasis, until the onset of LA contraction. In subjects with atrial fibrillation, the LA conduit phase has the same value as the LA reservoir strain but it is negative. LA booster strain: this occurs from the onset of LA contraction until end-diastole in patients with sinus rhythm. It always has a negative value.

J. Weerts et al.

![Comorbidities\nAtCM-atrial cardiomyopathy\nHealthy atria\nAtrial failure\nAbnormal geometry\nAbnormal wall structure\nEcho\n.LA diameter\n.LAVi\n.LA emptying fraction\nCMR\n.LA view\nIndirectly:\n.LAVi\n.LA area\n●Diastolic dysfunction\n●LAVi\n●LAVi\n●A wave velocity\n●PA-TDI duration(TACT)\n●LA mechanical\n●Mitral/tricuspid\ndispersion\n.LA strain\n.LA flow\nannulus diameter\n.-Degree of MR/TR\n(LA thrombus\nAbnormal\n](2/aj0YEe4oUhYkBdfpda0fYP/figure8926f45ac0144969bd07d91f7d6af17e_0_2.png) Figure 4 Evolution of atrial markers obtained by multimodal imaging. Multimodality imaging represents a useful approach to intercept subclinical changes in the left atrium, together with the surface electrocardiogram and serum biomarkers. Due to limited data currently, only indexed left atrial(LA) volume and LA reservoir strain are incorporated in the present atrial cardiomyopathy(AtCM) diagnostic framework.4D, four-dimensional; CMR, cardiac magnetic resonance; CT, computed tomography; LAVi, left atrial volume index; LGE, late gadolinium enhancement;MR,mitral regurgitation;PA-TDI(TACT),P-wave on surface electrocardiogram to peak A'-wave on tissue Doppler imaging(also known as the total atrial conduction time); TR, tricuspid regurgitation.

In contrast to the left ventricle, the left atrium presents a pressure-volume loop pattern with three main functional com-ponents: filling(or reservoir), passive emptying(or conduit), and active emptying(or booster pump). Each of these components is progressively hampered in diastolic dysfunction, with a gradual reduction of LA functional reserve. Atrial remodelling can be dis-tinguished into a functional component(consisting of an impaired function without necessarily an increment in size) and structural component(with altered geometry and/or wall fibrosis). Imag-ing techniques, most notably echocardiography and cardiac mag-netic resonance(CMR), as well as cardiac computed tomography(CCT) are able to capture different aspects of atrial remodelling(Figure 4).17,27,64

Left atrial function, particularly atrial contraction, is reflected by the amplitude and width of transmitral atrial-induced flow veloc-ity(a wave).65 The ratio with peak early mitral velocity(E/a ratio)has classically been used as an index of LA and left ventricular(LV)pressures. More recently, LA strain analysis has been introduced to estimate reservoir, conduit and booster function,66,67 for which practical recommendations have been released by scientific soci-eties66('how-to' explanations in Appendix 2 and Figure 3). LA strain depends on the preload, afterload, and intrinsic atrial contractility.Specifically, LASr is tightly coupled to LV longitudinal shortening and is strongly influenced by LV strain, LV end-diastolic pressure and pulmonary capillary wedge pressure.68-71 LA strain is use-ful for the assessment LV filling pressures, defining the severity of diastolic dysfunction, and establishing the diagnosis of HFpEF.72 Its role has been demonstrated for risk stratification in several

disease settings.13,73 For instance, LASr was shown to be a deter-minant for morbidity(e.g.HF) and cardiovascular mortality in the general population,74 as well as acute HF.71 Evaluation of LA func-tion may help identify patients at high risk of atrial arrhythmias75 and risk of ischaemic stroke,76,77 similar to use in those undergo-ing AF catheter ablation to establish propensity to maintain sinus rhythm.78 Given the relatively easy assessment of LASr and the available evidence as prognostic factor compared to other LA strain assessments, only LASr is included in this proposed definition of AtCM.

Normal ranges for two-dimensional(2D) echocardiography-derived LA strain have been established.79-81 Thresholds for abnor-mal LASr are proposed at<23%, with LA booster strain thresh-old<5% for ages 40-65 years and<8% in those>65 years.68-71,80 Three-dimensional(3D) strain analysis can also be conducted,however normative values remain unclear and the impact of different pathologies warrants further validation.82 Other func-tional metrics of potential value are LA emptying fraction,83 LA mechanical dispersion index84 and LA stiffness index,85 whereas tissue Doppler-based strain assessment has been superseded by speckle-tracking approaches.86 CMR-based feature tracking anal-ysis provides information on atrial deformation comparable to echocardiographic speckle tracking. The proposed CMR-derived cut-offs for abnormal LA function are<23% for LASr and<8%for LA booster strain.87-90 Table 3 provides common atrial imag-ing values to indicate AtCM,79,80,88-101 and multimodality atrial imaging has recently been reviewed in an ESC clinical consensus statement.102

ESC/HFA consensus statement on atrial cardiomyopathy

Table 3 Atrial imaging parameters used in clinical practice to define structural and functional alterations

||Echocardiography|Cardiac magnetic resonance imaging|Cardiac computed tomography| |---|---|---|---| |Strengths|Quick and easy to conduct with wide access Timely assessment of LA dimensions, LV/RV function, atrio-ventricular valves 3D analysis Speckle-tracking analysis|High spatial and contrast resolution Better reproducibility and lower variability Identification of LA appendage thrombus, LV/RV function, atrio-ventricular valves 3D analysis Tissue characterization(LGE,ECV,T mapping); Useful in pre-procedural planning (catheter ablation)|High spatial resolution Identification of LA appendage thrombus Presence for atrio-ventricular valves Better reproducibility and lower variability 3D analysis Possibility of feature-tracking analysis Tissue characterization(late iodine enhancement, ECV), epicardial adipose tissue characterization Useful in pre-procedural planning( catheter ablation, LA appendage| |Limitations|High interobserver variability (lower for 3D analysis) Limited spatial resolution Limited by acoustic windows Tissue characterization not available|Limited availability Use of contrast medium (gadolinium) Data on normal values|| |Proposed thresholds of abnormality suggestive for atrial cardiomyopathy|||| |Left atrium LA diameter (anteroposterior)|>40 mm in men >38 mm in women 91 2D:>40 ml/m2 >48 ml/m2 in women>65 years 3D:>41 ml/m2> [3D:>41 ml/m2 >48 ml/m2 in patients>65 years 80 >22 cm2 for SR patients >28 cm2 for AF patients96 LA reservoir strain 2D:<23%79,80,98|>42 mm in men >41 mm in women >60 ml/m2 3D:>78 ml/m259 $$>28cm^{292,97}$$ $$<23\%88-90$$|>45 mm in men >44 mm in women >2D:>73 ml/m2 3D:>78 ml/m259| |LA area|>48 ml/m2 for AF patients96|>28 cm292,97|| |LA reservoir strain|2D:<23%79,80,98|<23%88-90|No studies in sufficiently large populations to propose optimal cut-offs| |LA conduit strain|2D:<12% <9% in patients>65 years80|<21%99|| |LA booster strain|2D:<8% $8\% 88-90$||| |LA emptying fraction|2D:<48% $3D:<43\%$|<46% $80,94$|| |Right atrium RA volume indexed >36 ml/m2 in men 100 >61 ml/m2 in men >45 mm in women 94 by BSA >30 ml/m2 in women >54 ml/m2 in women 44 mm in women RA area >22 cm2101 in men >27 cm2 in men >18 cm2101 in women >24 cm2 in women 97||||

Note that studies vary in the methodology of assessment, inclusion or exclusion of appendage or venous structures, and automated or post-processing approaches.3D, three-dimensional; BSA, body surface area; ECV, extra-cellular volume; LA, left atrial; LGE, late gadolinium enhancement; LV, left ventricular; RA, right atrial; RV, right ventricular.

J. Weerts et al.

Diagnostic criteria for left atrial enlargement

Left atrial enlargement and geometrical changes typically result from chronically elevated LA pressures in non-AF patients.65,103 2D LA volume indexed for body surface area(LAVi) represents the most extensively investigated parameter of LA remodelling, pro-viding important prognostic implications,104 particularly in patients with HF or AF.105,106 In those with HF, adverse LA remodelling is associated with higher risk of death and HF hospitalization,with increases in LA diameter preventable through up-titration of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,107 and sodium-glucose co-transporter 2 inhibitors.108 LA size also predicts AF, stroke and mortality in the general pop-ulation.109,110 The proposed cut-off for diagnosing LA enlargement based on 2D echocardiography is LAVi>40 ml/m2, with a higher threshold of>48 ml/m2 for women aged>65 years80(Table 3).3D echocardiography and CMR have better spatial resolution and can enhance the accuracy of volume estimates. The proposed cut-offs for diagnosing atrial enlargement using 3D echocardiography LAVi are>41 ml/m2(>48 ml/m2 for women>65 years),80 and>60 ml/m2 using CMR-derived LAVi.94 Atrial enlargement has typically been measured at maximal volume on echocardiography, however min-imal LA volume may be more highly associated with clinical out-comes in patients with HF,111,112 albeit with greater measurement variability.113

Diagnostic criteria for atrial fibrosis

Atrial fibrosis is a primary manifestation of AtCM that is linked to the electrical, mechanical and structural alterations discussed,and associated with development of atrial failure, AF, HF and adverse events. Scientific understanding of atrial fibrosis and its relevance is advancing.114 Notably, atrial fibrosis manifests in var-ious forms, including reactive and replacement fibrosis.115 CMR can detect atrial fibrosis through late gadolinium enhancement(LGE),116 but this is limited by the spatial resolution of current CMR scanning in relation to the thin atrial wall. Furthermore, a variety of different acquisition and post-processing protocols are available which differ in both the amount and regional distribu-tion of detected LA fibrosis.117,118 Small studies suggest that LA LGE≥10-15% can predict incident atrial arrhythmias, stroke and arrhythmia recurrence after pulmonary vein isolation,119-121 but further research is clearly warranted prior to widespread clinical use. LASr correlates with the extent of histological atrial fibrosis in advanced HF patients, highlighting the possibility of echocar-diography as a surrogate measure.122,123 Due to limited histolog-ical validation,124 it remains unclear whether detected atrial fibro-sis, which relies on threshold settings of LGE wash-out, primarily identifies larger areas of replacement fibrosis or is also sensitive to reactive(endysomial and perimysial) fibrosis. CMR and CCT can be valuable tools for planning AF ablation125 and quantifying epicardial adipose tissue, which plays an important role in atrial remodeling.126

Future directions

Further study is needed on the relationship between LA struc-tural and functional alterations and AF/stroke occurrence, hard endpoints(cardiovascular mortality, HF hospitalization), as well as the response to drug therapy in HF with reduced ejection frac-tion(HFrEF) and HFpEF, and to percutaneous interventions for aortic and mitral valve disease. There is a clear requirement to identify cut-offs for LA size and function that have prognostic value or can stratify risk of AtCM. This includes optimal clini-cal thresholds that indicate atrial remodelling, for example with combined electrical/structural markers such as the total atrial con-duction time that measures duration from depolarization to active LA contraction.127 Histological validation of imaging modalities to quantify atrial fibrosis will be important to further our mech-anistic understanding of AtCM, and to quantify any reversal of atrial fibrosis in response to medical therapy and other interven-tions. This includes sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists which have known antifrotibric properties, but where the impact on atrial fibrosis development and progression is unclear.128

Role of the right heart and comorbidities in atrial cardiomyopathy

A notable gap exists in our understanding of the interactions between the right heart and AtCM. Similarly, the mechanisms whereby systemic conditions and non-cardiac comorbidities may influence cardiac remodelling and affect the electrophysiologi-cal and mechanical properties of the atria have not been fully elucidated.

The interplay between right heart abnormalities and LA dys-function has been explored in patients with HFpEF.109 The term‘disproportionate LA myopathy’ was introduced to describe a con-dition where LA dysfunction was more pronounced than expected based on observed LV dysfunction. Right heart dysfunction through enhanced left-to-right atrial interaction and heightened pericardial constraint may be a contributor to LA myopathy.109 The exacer-bation and progression of cardiovascular conditions with adverse cardiac remodelling because of systemic, non-cardiac comorbidi-ties is well established, and is particularly evident in HFpEF and AF.129-134 Physiological ageing, coupled with common comorbidi-ties such as hypertension, obesity, diabetes mellitus and valvular disease can all contribute to atrial remodelling.17,135 The obe-sity phenotype of HFpEF is characterized by right ventricular dilatation and LV diastolic dysfunction through pericardial con-straint and ventricular interdependence.136 Tricuspid regurgita-tion, causing right ventricular volume overload, may also lead to HFpEF and atrial myopathy.137,138 Comorbidities have been linked to reduced LA and right atrial strain parameters in paroxysmal AF, particularly when more than three conditions are present,including hypertension, diabetes, coronary artery disease, obesity,age>65 years, moderate-to-severe mitral regurgitation and kidney disease.139

ESC/HFA consensus statement on atrial cardiomyopathy

Whether incidence or progression of AtCM can be prevented through effective management of AtCM precursors requires dedi-cated clinical trials. In the interim, it may be reasonable to encour-age early aggressive management of risk factors and comorbidi-ties in selected patients to prevent or reduce the progression of AtCM. This is similar to the AF-CARE approach detailed in the 2024 ESC guidelines on AF. In patients with clinical AF,there were sufficient trials for class I recommendations to reduce arrhythmia recurrence and prevent AF progression by better man-agement of hypertension, diabetes mellitus and obesity,in addi-tion to enhancing exercise capacity and restriction of alcohol intake.4

Future directions

Collectively, systemic conditions and non-cardiac comorbidities have the potential to significantly influence cardiac remodelling and can impact the electrophysiological and mechanical properties of the atria. However, the mechanisms by which these effects occur are not fully understood and warrant further exploration through mechanistic studies, and potentially preclinical or experimental investigations.

Future molecular targets for atrial cardiomyopathy

New mechanisms can shed light on AtCM and the bidirectional relationship between AF and HF and its therapeutic targets.14,141 Here we provide promising insights into the evolving research on the development, diagnosis or progression of AtCM.

Biomarkers

B-type natriuretic peptides are used in clinical practice to diag-nose HF,142 although their utility for AtCM is unclear. The Atrial Cardiopathy and Antithrombotic Drugs in Prevention after Cryp-togenic Stroke(ARCADIA) trial used B-type natriuretic peptide(>250pg/ml) or P-wave terminal force to indicate AtCM, but was stopped early due to futility for the comparison between apixaban versus aspirin to prevent recurrent stroke.143 LA wall stretch also prompts atrial natriuretic peptide(ANP) release. The left atrium in a failing heart exhibits abundant yet defective ANP synthesis,144,145 leading to a relative deficit of the active ANP form.146 Altered processing and clearance of natriuretic peptides increase susceptibility to volume overload, acute decompensa-tion147 and progression of HF148 ANP exerts anti-hypertrophic effects on the left ventricle149 and may stimulate autophagy and mitophagy.150,151 and it exhibits anti-arrythmic properties, reduc-ing the likelihood of re-entry and preventing AF maintenance.152 In AF, ANP synthesis is initially stimulated but reverses with arrhythmia progression, with a negative correlation between ANP production and atrial collagen deposition. In contrast, exces-sive ANP production can lead to amyloid fibril deposition, iso-lated atrial amyloidosis and AtCM.153,154 Mid-regional proANP has emerged as a potentially-specific biomarker for AF155 and

AtCM in HFpEF,156,157 although distinct thresholds require further research.

Bone morphogenetic protein 10(BMP10) belongs to the trans-forming growth factor-beta family and is a novel biomarker for atrial remodelling and AF. As an atrial-specific ligand, higher plasma levels may reflect more severely altered atrial structure.158,159 Elevated BMP10 levels have been linked to increased risk of adverse cardio-vascular events, 160-164 higher AF recurrence after rhythm control,and late postoperative AF after cardiovascular surgery.165 The pre-cise interaction between BMP10 and AF or HF remains unclear,but may not be directly causal,166 hence the need for further inves-tigation in its role as a risk stratifier for AtCM.160,161,163,167

Atrial fibrosis

The pathophysiological mechanisms leading to atrial fibrosis are diverse, involving stretch-induced activation of fibroblasts, sys-temic inflammatory processes, activation of coagulation factors,and fibro-fatty filtrations.168 While activated fibroblasts are the principal cells involved in collagen synthesis, other cell types such as atrial myocytes, adipocytes, and immune cells also play crucial roles in sensing environmental factors that contribute to atrial fibrosis.169,170 On a microscopic scale, diffuse endomysial fibro-sis causes discontinuous conduction, longitudinal dissociation, and endo-epicardial dissociation of electrical activity during AF.171,172 Larger, patchy fibrosis areas on a macroscopic scale are more likely to anchor macro re-entrant circuits. Further relevant histopatho-logical findings have previously been summarized.18 The hetero-geneity of atrial fibrosis mechanism complicates the development of effective therapeutic strategies, but also presents an opportunity for innovation.128

Inflammasome

Metabolic and cardiovascular disorders, such as hypertension, obe-sity, diabetes, gut dysbiosis, chronic kidney disease and sepsis, are known to stimulate the activation of nucleotide-binding oligomer-ization domain-like receptor protein 3(NLRP3).173-180 Increased NLRP3 inflammasome activity in atrial cardiomyocytes, immune cells181 and fibroblasts182 mediates active interleukin-1β and interleukin-18 release and the promotion of a fibro-inflammatory cycle. This can contribute to atrial and ventricular structural and electrical remodelling, promoting AtCM and an AF-maintaining substrate by affecting action channel functionality and Ca2+ handling.Mechanistic studies are needed to elucidate the causal relationship between inflammasome activation in atrial cells and AtCM, as well as the efficacy of NLRP3-specific inhibitors. ${}^{177,179,183-188}$ It should be noted that clinical trials of conventional anti-inflammatory drugs such as colchicine have demonstrated a mixed response,189 with the largest randomized trials showing no significant prevention of AF:190,191

Electrical and anatomical remodelling

Cardiomyopathies associated with arrhythmia and diastolic dys-function often share intrinsic cardiac triggers that may underly

J. Weerts et al.

AtCM.192 Electrical remodelling, usually defined as shortening of the atrial effective refractory period and action potential duration, contributes to atrial arrhythmogenesis by promoting re-entrant activity.193 Novel therapeutic targets have been iden-tified, including inhibition of phosphodiesterase(PDE) type-8,particularly the atrial-selective PDE8B2 isoform,194 and upreg-ulation of the Ca2+-dependent SK current.195 Reactive oxygen species-dependent activation of Ca2+/calmodulin-dependent pro-tein kinase llc could also be an important target to prevent adverse remodelling.196 In HF, elevated filling pressures impose mechanical stress and chronic overload on the atria. This leads to varying degrees of atrial remodelling, but the precise molecu-lar mechanisms remain elusive.197 Genetic and non-genetic alter-ations in active and passive force generation at the sarcomere level can contribute to electrical dysfunction via altered myofila-ment Ca2+ sensitivity, sarcomere integrity, impaired contractility and disturbed coordination of signalling molecules, all of which could induce and maintain AF by causing re-entry-promoting atrial remodelling.198-200 Atrial cardiomyocytes exhibit Ca2+ handling and structural, but not electrical, remodelling in HFrEF patients,201 unless AF co-occurs.201 Ca2+-handling abnormalities that cause cellular triggered activity are likely the major trigger of AF in HFrEF,201 with AF subsequently producing electrical remodelling that promotes its maintenance.202 Mainly in HFrEF, reduced phos-phorylation of cardiac myosin-binding protein C leads to con-tractile dysfunction and Ca2+-cycling abnormalities, contributing to cardiac arrhythmias.203,204 In HFrEF, increased myocardial stiff-ness, titin isoform alterations and fibrosis result in heteroge-neous conduction that, when present in the atria, are a substrate for the persistence and propagation of atrial arrhythmias.205-207 Defective mitochondrial oxidative capacity, particularly fatty acid metabolism, appears to be present within atrial cardiomyocytes in AF208 and HFrEF.209 Restoring the fatty acid metabolism oxi-dation presents an opportunity to tackle both disorders,209,210 although glucose metabolism and comorbidities such as obesity are confounders. Further understanding these electro-mechanical mechanisms will be crucial to delineate the common and distinct triggers of these conditions, and their role in the pathogenesis of AtCM.

Epicardial adipose tissue

Epicardial adipose tissue has been implicated in the pathogen-esis of AF and HFpEF,211,212 and could influence progression of AtCM211,213,214 through atrial fat infiltration, release of pro-inflammatory and pro-fibrotic mediators, oxidative stress,altered ion currents, gap junction modulation, and autonomic dysfunction.211,215,216 Patients with HFpEF have more epicardial fat than controls or those with HFrEF,214,217 and more atrial epicardial adipose tissue when AF is co-occurring.212 The browning of adipocytes may offer protection against AF and other cardio-vascular conditions by mitigating inflammation and improving metabolic profiles.218 contrasting with that observed in HFpEF.219 The negative cardiometabolic effects of adipocytes may be more pronounced in women than men, potentially increasing the risk of AtCM and a HFpEF phenotype in women.220

Clinical application, gaps in evidence and future directions

To diagnose and stratify AtCM, we suggest a comprehensive assess-ment of clinical status, evaluation of electrical atrial dysfunction using ECG to assess for P-wave abnormalities, and imaging to deter-mine mechanical atrial dysfunction and atrial enlargement. The lat-ter is most commonly interrogated with echocardiography(includ-ing speckle-tracking analysis), with CMR considered as a comple-mentary examination, especially when better resolution or tissue characterization is clinically indicated. It is essential to integrate the assessment of the left atrium with thorough evaluation of LV sys-tolic and diastolic function, valve disease and the right heart.This comprehensive approach will allow the exclusion of other struc-tural heart alterations as a cause of symptoms, and put the potential diagnosis of AtCM in context. The presence of any one AtCM marker(electrical atrial dysfunction, mechanical atrial dysfunction,atrial enlargement or excessive atrial fibrosis) should prompt this diagnostic work-up. However, electrical atrial dysfunction plus one of the structural markers is required under this proposed defi-nition to confirm AtCM, in order to avoid over-diagnosis. This is a key development over previous AtCM definitions, with the enhanced specificity designed to stimulate new clinical research and trials that can demonstrate opportunities to prevent AtCM or its progression.

Regardless of whether a patient is deemed at risk or with AtCM,they should undergo detailed screening for HF using imaging and natriuretic peptides, and appropriate ECG monitoring for atrial arrhythmias as outlined in the respective ESC guidelines.2-4 The role that gender plays on risk stratification or management of AtCM is unclear, although studies have demonstrated that women have a higher prevalence and more extensive regions of low-voltage zones in the left atrium than men221,222 that could indicate more advanced underlying cardiomyopathy by the time of diagnosis or treatment. AtCM with confirmation of either HF or persistent AF provides a diagnosis of atrial failure that requires therapy for each condition as per clinical guidelines,2-4 with the potential for prog-nostic benefit. Considering the high risk of adverse outcomes in patients with AtCM and atrial failure, monitoring by a cardiolo-gist with either HF or AF expertise is advisable, depending on local infrastructure. Important evidence gaps and possible future research directions for the AtCM diagnostic framework are sum-marized in Table 4,101,223-234 with the aim of galvanizing AtCM research, and providing clearer diagnostic cut-offs for clinical use and enhancing their implementation in routine practice.

Conclusions

Atrial cardiomyopathy is a progressive condition that starts from apparently healthy atria, traverses a subclinical phase of atrial dis-ease, and continues to an end-stage of atrial failure that has irre-versible consequences for the patient. This paper, coordinated by the HFA of the ESC and supporting early career investigators, was designed to stimulate the field, coalesce research targets and facil-itate future clinical trials to prevent progression of AtCM. We

ESC/HFA consensus statement on atrial cardiomyopathy

Table 4 Important evidence gaps in atrial cardiomyopathy and suggested future directions

|Evidence gaps|Future directions| |---|---| |Expected clinical course of the AtCM spectrum and relevant clinical markers|● More population and mechanistic studies are needed to identify the natural course of AtCM and its relation to clinically relevant outcomes.Specifically,are there features or markers that indicate a higher risk of stroke, thromboembolism or progressive HF development in individuals with or at risk of AtCM? ● How do common comorbidities(such as hypertension, obesity, diabetes mellitus and coronary artery disease) or lifestyle(smoking,obesity and exercise) as well as treatment impact the course of AtCM? ● Do women have the same trajectory for AtCM development and progression as men after accounting for biology and diagnostic/treatment biases? ● Which underlying causes lead to AtCM independent of left ventricular, right heart or valvular dysfunction? ● Secondary functional mitral or tricuspid valve regurgitation due to atrial remodelling(enlargement) may indicate progressed atrial failure, but what are important modifiable factors in this process?101,223,224| |AtCM diagnostic framework is not clinically validated|● Well-powered studies are essential to improve this diagnostic framework for AtCM. ● Evaluation and refinement of the AtCM diagnostic framework in retrospective and prospective studies requires careful balancing for age, gender, cardiovascular risk factors and history of cardiac disease. ● Registry data on HF are essential to comprehensively assess AtCM/atrial failure prevalence across the ejection fraction spectrum. ● Attention is needed on the interaction and ability to distinguish between AtCM-related atrial failure and HFpEF phenotypes.| |Serum biomarkers to facilitate AtCM diagnosis|● Studies exploring the role of a range of natriuretic peptides, corin, and BMP10 biomarkers in diagnosing AtCM or identifying targets for therapy, including relevant clinical cut-points. ● Explore the clinical relevance of implementing ambulatory rhythm devices, such as wearables, photoplethysmography signal processing, and implantable devices, within the AtCM framework. 225-229| |Easily obtained or clinically reliable parameters to facilitate AtCM diagnosis|● The role of invasive techniques such as atrial high-density electro-anatomical mapping for the diagnosis of AtCM and prognostic stratification requires further investigation. ● Which artificial intelligence algorithms can improve the AtCM diagnostic framework and selection for future therapies? ● Reproducibility of imaging parameters is poor in the context of AF, with further data awaited on alternative approaches such as the index-beat method of acquisition following two preceding R-R intervals of similar duration.230| |Uncover additional manifestations of atrial failure|● Further studies on the relationship between left atrial structural and functional alterations and AF/stroke occurrence, hard endpoints(mortality, hospitalization), as well as response to optimized medical therapy.| |The role of right heart dysfunction in AtCM|● Right heart dysfunction and its impact on AtCM development requires further dedicated imaging studies.| |Patient selection for future clinical trials and the threshold of AtCM markers to initiate therapy and prevent disease progression|● Identification of AtCM markers with strong prognostic value that can aid patient selection for clinical trials to improve outcomes. ● Randomized controlled trials assessing the use of anticoagulants in individuals with AtCM but without AF are needed to enhance our understanding of the impact of AtCM on stroke and thromboembolism. ● Studies on relevant atrial fibrosis cut-off values by cardiac magnetic resonance imaging to diagnose AtCM are needed. ● The digital twin approach231 could enhance (pre-)clinical research by providing a platform for studying the isolated and interconnected effects of the specific disease subsets that are relevant to the AtCM spectrum. This involves validating and translating these models for practical clinical applications, necessitating further research to seamlessly integrate theoretical frameworks into real-world healthcare practices. Examples include improved ability to distinguish anatomical versus functional factors underpinning specific P-wave disorders to redefine ECG-based risk prediction for AtCM, or to better phenotype AtCM on tissue property levels such as atrial myocardial compliance and contractility.|

J. Weerts et al.

Table 4(Continued)

|Evidence gaps|Future directions| |---|---| |The effect of therapies on AtCM substrates and clinical outcomes|The potential benefit of using anticoagulant and antiarrhythmic therapy in patients with pathological P-wave parameters in the absence of atrial arrhythmias is controversial and requires further investigation. ● What kind of clinical benefit can be achieved with anti remodelling treatments(such as neprilysin or sodium-glucose co-transporter 2 inhibitors) in patients with early stages of AtCM? ● The appropriate ablation strategy in patients with AF and advanced AtCM, and its ability to modify substrate and disease progression, requires specific investigation. ● What patient outcomes are relevant for those with AtCM, what could predict atrial failure, and what is the optimal way to monitor and subsequently intervene in selected populations? ● Future research should focus on elucidating the inflammasome effect on cardiac electrophysiology mechanisms to halt or reverse and AF pathogenesis, and delineating their role in cardiomyocyte inflammatory signalling with fibroblasts and immune cells. Are selective inhibitors for these pathways effective at preventing development of AF or HF? ● Studies are needed to assess the efficacy of inhibitors in the electrical remodelling pathway, explore the regulation of atrial ion channels and calcium handling, and identify genetic predispositions to HF (for example, through PITX232-234). ● Future research should investigate the influence of epicardial adipose tissue on atrial fibrosis, sex-dependent mechanisms and the relationship with inflammation. ● Patients with AF and without AtCM who eventually develop atrial failure are of special interest to deepen the understanding of the AtCM framework.|

AF,atrial fibrillation; AtCM,atrial cardiomyopathy; BMP10, bone morphogenetic protein 10;ECG,electrocardiography;HF,heart failure; HFpEF,heart failure with preserved ejection fraction.

propose a new pragmatic framework for AtCM based on elec-trophysiology,imaging,biomarkers,and clinical status.Straightfor-ward criteria are suggested to confirm electrical atrial dysfunc-tion, mechanical atrial dysfunction and atrial enlargement in the clinical environment. Atrial fibrosis is an important part of the proposed AtCM definition, with further preclinical and clinical evi-dence required to understand its role in AtCM stratification. Earlier detection of AtCM utilizing a range of developing and promising tar-gets could harness novel therapeutics, or repurposing of existing therapy, to prevent overt atrial failure, AF, HF and their sequelae.

Acknowledgements

This consensus statement has been endorsed by the ESC Clinical Practice Guidelines Committee and approved by the ESC Scientific Documents Committee. The authors would like to acknowledge Dr. Karina Bunting (University of Birmingham and University Hos-pitals Birmingham NHS Foundation Trust, UK) for expert assis-tance on cardiac imaging in atrial fibrillation, and expert insights from the ESC Heart Failure Association Scientific Documents Committee Reviewers. The authors are also grateful to Mr. Geof-frey Grolier Chapelau(ESC Councils Coordinator) and Ms. Lau-rence Fani(ESC Working Groups Coordinator) for their proficient logistic support.

Conflict of interest: J.W. reports personal fees from Corvia Medical,CSL Vifor, and Boehringer Ingelheim, outside the submitted work. C.B.declares HFA clinical training grant and Italian Society of Cardiology train-ing grant. C.W. reports that his employer(University Medical Center Groningen) has received research grants and/or fees from AstraZeneca,Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis

Pharmaceuticals, Inc, Novo Nordisk, and Roche. D.Z. reports payment for expert testimony from Krka, Boehringer Ingelheim for honoraria for lectures. M.A. reports payment or honoraria for lectures, presentations,speakers' bureaus, manuscript writing or educational events from Abbott Vascular and Edwards Lifesciences. E.A. declares grants or contracts from Fundació La Marato'Tv3,(Projecte 245/U/2020); consulting fees from Bayer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or fiduciary role in other board, society, committee or advocacy group-in EHRA board member unpaid. F.B.V.B. reports as leader-ship or fiduciary role in other board, society, committee or advocacy group that he is a member of working group on Atrial Myopathy unpaid. D.T.F.declares consulting fees from Boehringer Ingelheim, Leo, Viarris; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Leo, Novartis, Removing Board or Advisory Board on behalf of Boehringer Ingelheim, Leo. D.D. declares consulting fees AbbVie Deutsch-land GmbH& Co.KG, consultancy about poAF, honorarium; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or honoraria for lectures, previous presentations, speakers bulaus, manuscript writing or educa-Vifor; and participation in a Data Safety Monitoring Board or Advisory Board

ESC/HFA consensus statement on atrial cardiomyopathy

Board for Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Medronic,Novartis,Pfizer,ReCor,Svier,Vifor,A.C.Rports consulting fees from GSK,Menarini,Novartis,Novo Nordisk,Servier,Vifor,Abbott,Actimed,Cardiac Dimensions, Corvia,CVRx,Reupena,ESN Clear,Farady,Impulse Dynamics, Respicardia, Viatis; payment or honoraria for lectures, presen-tations, speakers bureaus, manuscript writing or educational events from AstraZeneca,Bayer, Boehringer Ingelheim, Edwards, Eli Lilly; participation in a Data Safety Monitoring Board or Advisory manufacturers, from the last 3 years, Roche-Stratctural Heart, AstraZeneca,Bayer,Boehringer Ingelheim, Edwards Lifesciences, Novo Nordisk- minimal amounts in the last 3 years.G.R.de declares consulting fees from AstraZeneca,Bayer,Boehringer Ingelheim, Edwards Lifesciences, Novo Nordisk- minimal amounts in the last 3 years.G.R.declares consulting fees from AstraZeneca,Bayer,Boehringer Ingelheim, Vifor Pharma, Medronic, Servier, Viarris, Anlyram,Boehringer Ingelheim, Medtronic, Viatis; support for attending meetings and/or travel from Gelfaernin: participation in a Data Safety Monitoring Board or Advisory Board for Fair-HF2, Reshape-HF2. FR. declares grants or contracts from any entity, he has not received personal payments by pharmaceutical companies or device manufacturers in the last 3 years(remuneration for the time spent in activities, such as participation as steering committee member of clinical trials and member of the Pfizer Research Award selection committee in Switzerland, were made directly to the University of Zurich). The Department of Cardiology(Univer-sity Hospital of Zurich/University of Zurich) reports research, educational and/or travel grants from Abbott, Abiromed, Alnylam, Amarin, Agena,AstraZeneca, At the Limits Ltd., Bayer, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, Bracco, CM Microport, Concept Medical, CTI,Daiichi Sankyo, Edwards Lifesciences, FomF GmbH, Hamilton Health Sci-ences,HIF, Innosuisse, lumiraDX, Kantar, LabPoint, MedAlliance, Medcon International, Medical Education Global Solutions, Medronic, MicroPort,Monocle, Novartis, Novo Nordisk, OM Pharma, Pfizer, Quintiles Switzer-land Sari, RecorMedical, Roche Diagnostics, Roche Pharma, Sahajanand IN, Sanofi, Sartstedt AG, Servier, Terumo Deutschland, Trama Solutions,V-Wave, Vifor, ZOLL, consulting fees from SrainaZeneca(MIC), Bayer, Boehringer Ingelheim, Citi Research, Klub Class, Novo Nordisk, Radcliffe Group, Sftung Pfizer Forschungspreis, Vlior, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educa-tional events from Abbott, Amgen, AstraZeneca(A+ Science AB), Bayer(At the Limits), Boehringer Ingelheim, Boston Scientific(CCE Services),Brigham and Women's Hospital Boston, C.T.I GmbH, Fomf, Hopitaux Uni-versaires des Geneve(GECORE), Luzner Kantonspatial, Sanofi-Avents,Servier, Medcon, Medscape(WebMD), Medtronic, Medworld, Novartis,Roche, Ruagw, Swiss Heart Failure Academy, The Hong Kong Heart Failure Stariage, Trama Solutions SL, Inselspital Bern, Charité- Universitatsmedizin Berlin (Medical Education Global Solutions), Romanian Society of Car-diology, OK G Kosterreich Gesellschaft fur Kardiologie, Zoll; sup-port for attending meetings and/or travel from AstraZeneca(IMC/A+Science AB), Boehringer Ingelheim, Centro Hospitaler de Vila Nova de Gaia, C.T.I. GmbH (Universitasklinkim Dusseldorf), European Society of Cardiology, Monocle, Novarts, Spektar Putovania, Austrian Heart Failure Association, Heart Failure Association of the ESC; participa-tion in a Data Safety Monitoring Board or Advisory Board for Bayer:HF Expert Summit, Advisory Board Meeting: Roche, IMC/AstraZeneca,Amgen.A.B.G. has lectured and participated in advisory boards for Abbott, AstraZeneca, Bayer, Boehringer-Ingelheim, Medtronic, Novar-tis, Novo Nordisk, Roche Diagnostics, Vifor. D.K. reports grants from the National Institute for Health Research(NIHR CDF-2015-08-074-RATE-AF;NIHR130280 DaRe2THINK;NIHR132974 D2T-NeuroVascular;NIHR203326 Biomedical Research Centre), the British Heart Foun-dation(PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), the

EU/EPIA Innovative Medicines Initiative(BigData@Heart 116 074), EU Horizon and UKRI(HYPERMARKER 101095480), UK National Health Service-Data for R&D-Subnational Secure Data Environment programme,UK Dept. for Business, Energy& Industrial Strategy Regulators Pioneer Fund, the Cook& Wolstenholme Charitable Trust, and the European Society of Cardiology supported by educational grants from Boehringer Ingelheim/BMS-Pfizer Alliance/Bayer/Daiichi Sankyo/Boston Scientific, the NIHR/University of Oxford Biomedical Research Centre and British Heart Foundation/University of Birmingham Accelerator Award(STEEER-AF). In addition, he has received research grants and advisory board fees from Bayer, Amomed and Protherics Medicines Development; all outside the submitted work. All other authors have nothing to disclose.

Appendix 1 How to perform P-wave analysis

The P-wave duration marks the beginning and end of atrial electrical activity. Hence, exact marking is of utmost importance for any further analysis of P-wave parameters, such as inter-atrial block(IBA) and others. The measurement of P-wave duration can be performed using various techniques.

Routinely, P-wave duration is measured via a standard 12-lead electrocardiogram(ECG)(e.g. recorded 6-12s, 200 Hz sample frequency, bandwidth filtering 0.05-100 Hz) by marking the ear-liest onset of the P-wave in any lead of the frontal plane, and the lead where the end of P-wave is recorded(especially lead I, V5 and V6, and aVR and in some cases V1[sagittal force])(see Figure 3).The interval between these two points(it is recommended to trace vertical lines) will be the total P-wave duration(Figure 3A,Steps 2a and 3a). While the onset of the atrial electrical activity is usually clearly seen, the end of atrial electrical activity is more difficult. It can be complicated by small amplitude electrical activ-ity,in particular in atria with inhomogeneous electrical propagation and different conduction properties such as seen in patients with atrial cardiomyopathy(AtCM). These small atrial electrical activi-ties can be filtered out by routine filtering techniques. It should be noted that measurement of the P-wave can underestimate the real duration, especially if the P-wave has low amplitude.

Several more sophisticated techniques are available to measure the P-wave duration by means of ECG amplification or by calculat-ing a signal-averaged P-wave. When performing an amplified P-wave duration(aPWD) measurement, it is paramount to amplify the dig-ital ECG recording to visualize also the low amplitude parts of the P-wave in patients with AtCM. To achieve a good ECG quality, fil-ter settings should be set to 0.05 to 100 Hz without additional noise filtering at a sample rate of 1000 Hz. For measurement of a PWD, the digital ECG should then be amplified to 40-80 mm/mV with a sweep speed of 100 to 200 mm/s. Calculation of a signal averaged P-wave requires several P-waves for a robust result. It is recommended to consider 300 P-waves which equals approxi-mately 5 min of recording time. The recording should be performed without any applied filter and in high-resolution(1000 Hz or more).The signal-averaged P-wave is calculated as a mean signal out of all recorded unfiltered P-waves. Any random artefacts superimposed on the unfiltered signal disappear, but small changes in the electri-cal propagation will be preserved in the resulting signal-averaged P-wave(Figure 3A, Step 2b and 3b).

J. Weerts et al.

Inter-atrial block is defined as a P-wave of 120 ms or more and is classified into three degrees of block: partial(P-wave≥120 ms with normal axis and usually bimodal morphology); intermittent(variable degree of IAB detected on the same ECG record-ing); and advanced(or third-degree IAB, with P-wave≥120 ms plus biphasic morphology[positive-negative] in the inferior leads II, III and aVF). Some atypical patterns of advanced IAB have been described, by duration(P-wave<120 ms with biphasic mor-phology), or by configuration(with‘positive-negative-positive morphology or with the presence of isodiphasic components).Nevertheless, in all cases of advanced IAB there will be a final neg-ative component in a VF, reflecting retrograde activation of the left atrium.

Appendix 2 How to perform left atrial echocardiography

Left atrial(LA) size and function should be measured using a non-foreshortened view(as much LA length as possible) in the apical four-chamber and/or two-chamber view. A good quality electrocardiogram(ECG) trace is mandatory, with clearly visible P-wave.

Indexed left atrial volume

The preferred method to quantify LA size is the volumetric method because it accounts for variations in the shape of the left atrium.There are two different principles with which volumes can be obtained: the area-length method and the method of discs(Simpson method). For both methods, tracing of the atrial cavity is required. LA length is measured from the centre of the connecting line between both sides of the mitral annulus to the LA roof.For Simpson, this is done on a four-chamber view at end-systole,shortly before the mitral valve opens. For the biplane approach,which is even more exact, also use a two-chamber view. The volume obtained should be indexed for body surface area(LAVi).

Left atrial strain

We recommend to use a speckle tracking technique and measure atrial function using ECG R-R gating, with baseline at zero on four- or two-chamber views. Depth should be adjusted to enlarge the left atrium and ensure it is fully visualized, including the roof of the atrium without foreshortening(Figure 3B). The left atrium should be focused in four- and/or two-chamber view, obtained with narrow image sector, in order to improve the definition of the grey-scale image and frame rate. Use the mid-wall contour of the atrium cavity from one to another mitral ring point, leaving pulmonary veins and atrial appendix excluded from the contour.Adequate measurements are achieved if the region is around 3 mm thin and covers only the LA myocardium. The zero reference is end-diastole and multiple or index beats should be analysed where sinus rhythm is not present.

References

1. Williams JRJF, Sonnenblick EH, Braunwald E. Determinants of atrial contractile force in the intact heart. Am J Physiol 1965;209:1061-1068. https://doi.org/10.1152/ajplegacy.1965.209.6.1061

2.McDonagh TA,Mraem M,Adamo M,Gardner RS,Baumbach A,Bohm M,et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). With the special contribution of the Heart Failure Journal 2022;24:4-131.https://doi.org/10.1002/ejhf.2333

3.McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M,et al. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology in(ESC). With the special contribution of the Heart Failure Association(HFA) of the ESC. Eur J Heart Fail 2024;26:5-17.https://doi.org/10.1002/ehf.3024

4. Van Gelder I,Criestra M,Bunting KV, Casado-Arroyo R,Caso V,Crijns H,et al.2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS). Eur Heart J 2024;45:3314-3414.https://doi.org/10.1093/eurheartj/ehae176

5.Chugh SS, Hammoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ,et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation 2014;129:837-847. https://doi.org/10.1161/CIRCULATIONAHA.113.005119

6.Piccini JP,Hammill BG,Snir MF,Jensen PN,Hernandez AF, Heckbert SR,et al.Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries,1993-2007.Circ Cardiovasc Qual Outcomes 2012:5-85-93.https://doi.org/10.1161/CIRCOUTCOMES.111.92688

7. Mobley AR, Subramanian A, Champs A, Wang X, Myles P, McGreavy P, et al.Thromboembolic events and vascular dementia in patients with atrial fibrillation and low apparent stroke risk. Nat Med 2024;30:2288-2294.https://doi.org/10.1038/s41591-024-03049-9

8.Roy D,Talajic M,Nattel S,Wyse DG Dorian,P Lee KL,et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-2677.https://doi.org/10.1056/NEJMoa0708789

9.Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al;ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-129.https://doi.org/10.1056/NEJMoa10510557

10. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al;ASSERT Investigators. Temporal relationship between subclinical atrial fibril-lation and embolic events. Circulation 2014;129:2094-2099.https://doi.org/10.1161/CIRCULATIONAHA.113.007825

11.Zhang Michael J,Ji Y,Wang W,Norby Faye L, Parikh R,Eaton Anne A,et al.Association of atrial fibrillation with stroke and dementia accounting for left atrial function and size.J.ACCAdv 2023:2:100408.https://doi.org/10.1016/j.jaccad.2023.100408

12. Wang W, Zhang MJ, Incardiari RM, Norby FL, Johansen MC, Parikh R, et al.Association of echocardiographic measures of left atrial function and size with incident dementia. JAMA 2022;327:1138-1148. https://doi.org/10.1001/jama.2022.2518

13.Weerts J, Barandiarán Aizpurua A, Henken M, Lyon A, van Mourik MJW, van Gemert M, et al. The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. Eur Heart J Cardiovasc Imaging 2021:23:74-84.https://doi.org/10.1093/ehci/jeab222

14. Hart RG, Sharma M, Mundl H, Kasner SE, Bangwala SIk, Berkowitz SD, et al;NAVIGATE ESUS Investors, Rivoxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-2201.https://doi.org/10.1056/NEJMoa1802686

15.Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mund H, Epstein AE,et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: Secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol 2019;76:764-773. https://doi.org/10.1001/jamaneurol.2019.0617

16. Nagle R,Smith B,Williams DO. Familial atrial cardiomyopathy with heart block.Br Heart J 1972:34:205

17. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al.EHRA/HRS/APHS/RSOLAACE expert consensus on atrial cardiomy-opital:Definition, characterization, and clinical implication. Eurospace 2016;18:1455-1490.https://doi.org/10.1093/europace/euw161

18.Goette A, Corradi D, Dobrev D, Aguinaga L, Cabrera JA, Chugh, S et al.Atrial cardiomyopathy revisited- evolution of a concept: A clinical consensus statement of the European Heart Rhythm Association(EHRA) of the ESC,the Heart Rhythm Society(HRS), the Asian Pacific Heart Rhythm Society(APHRS), and the Latin American Heart Rhythm Society(LAHRS). Europace 2024;26:eueua204.https://doi.org/10.1093/europace/euae204

$$\text{ ESC}/\text{ HFA}\text{ consensus statement on a etrial cardiomyopathy}$$

19. Marcou Exosonowski D, Ninni S, Mackasey M, Cadrin-Tourigny J, Roberts JD,et al. Genetic atrial cardiomyopathy: Common features, specific differences,and broader relevance to understanding atrial cardiomyopathy. Circ Arrhythm Electrophysiol 2023;16:675-698.https://doi.org/10.1161/circicp.123.003750

20. Piruccello JP,Diachille P,Choi SHo,JPia RomT,Khurshid S,Nekoui M,et al. Deep learning of left atrial structure and function provides link to atrial fibrillation risk.Net Commun 2024:15.4304.https://doi.org/10.1038/14467-024-48229-w

21.Ahberg G.,Andreasen L,Ghouse J,elsen B, Lundgaard H, Haunse S, et al.Genome-wide association study identifies 18 novel loci associated with left atrial volume and function. Eur J 2017;42:4523-4534. https://doi.org/10.1019/009/heart/ehab466

22.Coats AJs, Heymans, Farmakis, D Anker, On Sko, Backs J., Bayersuats, J. et al.Atrial disease and heart failure: The common hypothesis hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2022:43:863-867.https://doi.org/10.1093/eurnerh/ehab834

23. Martinez-Selles M, Orosela R, Ibarola R, de Andres M, Diez-Willaeva P,Bayes-Genis A,et al.; BAYES Registry Investors. Advantages of interbital block and P-wave duration are associated with atrial fibrillation and stroke in older adults with heart disease: The BAYES registry. Europe 2020;22:1001-1008.https://doi.org/10.1093/europace/aeuaa114

24. Pathan F, D'Elia N,Nanol M, Marwick, ThN, Negahki K. Normal ranges of left atrial strain by speckle-tracking echocardiography: A systematic review and meta-analysis.J Am Soc Echocardiogr 2017;30:59-70.e8.https://doi.org/10.1016/j./echo.2016.09.007

25. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D, Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995,92:835-841.https://doi.org/10.116/11.01/cir.92.43.853

26. Larsen BS, Kumarathai P, Falkenbergen J, Nielsen OW, Sajadie A. Excessive arial octet and short atrial runs increase the risk of stroke beyond incident atrial fibrillation.J Am Coll Cardiol 2015;66:232-241.https://doi.org/10.1016/j.jacc.2015.05.018

21. Birbal F, Banchuk A, Brambu N, Bayed U, Bayes L A, Bayes-Genis A. Arial failure as a clinical entity: JACC review topic of the week. J Am Coll Cardiol 2020;75:222-232.https://doi.org/10.1016/j.jacc.2012.11.013

28. Hindrings G, Potopara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C,et al.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic surgery(EACTS): The lask Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC). Developed with the special contribution of the European Heart Rythmology (EHRAs) of the ESC. Eur J Heart 2020;42:373-498.https://doi.org/10.1039/eurieh/haehq1/2019

29.Noseworthy PA, Atti Zia, Belhken EM, Giblen R, Beams R, Liu S, et al. Arti-fical intelligence-guided screening for atrial fibrillation using electrocardiogram during sinus rhythm: A prospective non-randomised interventional trial. Lancet 2022:400-1261212.https://doi.org/10.1016/s1016/0140-6736(2022)16167-3

30. Gill SK, Kawah, U.H. HW, Cardoso VR, Gu Z, Barsky A, Ref. All-Big Data@Heart Consortium and the cardAlc group. Artificial intelligence to enhance clinical value across the spectrum of cardiovascular healthcare. Eur Heart J 2023;44:713-725.https://doi.org/10.1016/j.1093/eurheart/ehac758

31. van Campenhout MJ, Yaksh A, Kik C, de Jaegere PP, Ho SY, Allessie MA, et al.Bachmann's bundle: A key player in the development of atrial fibrillation: Circ Arrhythm Electrophysiol 2013;6:1041-1046.https://doi.org/10.1161/circep.113.000758

32. Chen LY,Ribeiro ALP, Photonouy PG,Cyanckiewicz,I.Solman Z,Eorgnek B,et al.P wave parameters and indices: A critical appraisal of clinical chal-lenges, and future research- a consensus document endorsed by the Interna-tional Society of Electrocardiology and the International Society for Holmer and Noninvasive Electrocardiology. Circ Arrhythm Electrophysiol 2022;10:010435 https://doi.org/10.1016/circp.12:010435

33. de Luna AB,Masso-van Roessel A, Robledova L.E. The diagnosis and clinical implications of intermaterial block. Eur Cardiol 2015;10:54-59. https://doi.org/10.15240/ec/12015.101.045

41. Ariyarah J, VApiasawat, Suri P, SpodicDH. Specific electrocardio-graphic markers of P-wave morphology in cardiac production. J. Electrochel.2006;39:380-384.https://doi.org/10.1016/j.jelectrocard.2005.11.002

35. Power DA, Lampert J, Camaj A, Bienstock SW, Kocovic N, Bayes-Genis A,et al. Cardiovascular complications of interfacial conduction block; JACC state-of-the-art review.J Am Coll Cardiol 2022;79:1199-1211.https://doi.org/10.1016/j.jacc.2022.01.030

36. Philotpe: MS.Eastday BC, Hinshaw V. Antigenic and phenotypic variants of a virial anu virian virus selected during replication in ducks. J Wild Dis 1989:25:507-513.https://doi.org/10.7589/0090-3558-25.4.507

37.Hmad ML,Mujaba M,Floyd JS,Chen YL,Solan EZ,Electrocardo-graphic markers of atrial cardiomyopathy and risk of heart failure in the

Multi-Ethnic Study of Atherosclerosis(MESA) cohort. Front Cardiovasc Med 2023:10:114338.https://doi.org/10.3389/fcmv.2023.1143338

38. Diener HC, Har CRG, Koudstaal PJ, Lane DA, Lip GYH. Atrial fibrillation and cognitive function: J: ACC review of the topic. We J Am Coll Cardiol 2019;73:612-619.https://doi.org/10.1016/j.jacc.2018.10.077

39. Baranchuk, A Torner P, de Luna AB. Bayes syndrome: What is? Circulation 2018:137-200-202. https://doi.org/10.1161/CIRCULATIONAHA.117.032333

40.Zoragidis K, Koutalus E, Intzes S, Symeonodid M, Zagoridou N, Karagogos K,et al. P-wave duration and intertrial block as predictors of new-onset atrial fibrillation: A systematic review and meta-analysis. Hell J Cardiol 2023;72:57-64.https://doi.org/10.1016/j.hjc.2023.03.007

41.Muller-Edenborn B, Chen J, Algeier J, Didenko M, Moreno-Weidmann Z,Neumann FJ, et al. Amplified sinus-P-wave reveals localization and extent of left atrial low-voltage substrate: Implications for arrhythmia freedom following pulmonary win isolation. Europace 2020;22:240-249. https://doi.org/10.1093/europe/euz297

42. Maheshwari A,Norby FL,Soliman EZ,Alraies MC,Adabag S,O'NealWT,et al.Relation of prolonged P-wave duration to risk of sudden cardiac death in the general population(f the Atherosclerosis Risk in Communities study. Am J Cardiol 2017;119:132-1306.https://doi.org/10.1016/j.amjcard.2017.01.012

3.Jadjad A,Muller-Edenborn B,Chen J,Keyl C,Weber R,Algeier J,et al.The dura-tion of the amplified sinus-P-wave identifies presence of left atrial low voltage substrate and preduce outcome after pulmonary vein isolation in patients with persistent atrial fibrillation.JACC Clin Electrophysiol 2018;4:531-543.https://doi.org/10.1016/j.jacep.2017.12.001

44.Nielsen J,B.Kuji JT,Petersen A,Graff C,Lind B,Strujijk J,et al.P-wave duration and the risk of a fibrillation: Results from the Copenhagen ECG Study. Heart Rhythm 2015;12:1887-1895.https://doi.org/10.1016/j.hrthm.2015.04.026

45. Eichenlaub M. Mueller-Edenborn B, Minners J, Jander N, Allgeier M,Lehrmann H, et al. Left atrial hypertension, electrical conduction slow-ing, and mechanical dysfunction- the pathophysiological triad in atrial fibrillation-associated atrial cardiomyopathy. Front Physiol 2021;12:670527.

46. Ghassemi MM, ModoBE, Lehman LH, Song C, Li Q, Sun H, et al. You snooze,you win: The physioctonic computing in cardiology challenge 2018. Comput Cardiol 2018:45:1-4.https://doi.org/10.22489/cinc.2018.049

7. Cethenlaus M, Mueller-Edenborn B, Lehrmann H, Minners J, Nairn D, Loewe A,et al. Non-invasive surface surface electrocardiographic imaging for diagnosis of atrial cardiomyopathy. Europe 2021;23:2010-2019. https://doi.org/10.1093/eurporabue 140

48. Moreno-Weidmann Z, Mueller-Edenborn B, Jadidi AS, Bazan-Gelizo V, Chen J,Park Cl,et al.Easily available ECG and echocardiographic parameters for prediction of left atrial remodeling and atrial fibrillation recurrence after pulmonary vein isolation: A multicenter study. J Cardiovasc Electrophysiol 2021:32:1584-1593.https://doi.org/10.1111/jce.15013

49. Lankelved T, Zemering S, Scherr D, Kuklik P, Hoffmann BA, Willems S, et al.Atrial fibrillation complexity parameters derived from surface ECGs predict procedural outcome and long-term follow-up of stepwise catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2016;9:e003354. https://doi.org/10.1161/CIRCEP.115.003354

50. Pose M,Lankelved TA,Zaemering S,Dagnelie PC,Stehower CD, Henry RM,et al.P-wave complexity in normal subjects and computer models.J.Electcardrool 2016:49:545-553. https://doi.org/10.1016/j.jelectrocard.2016.05.005

51. Zink MD, Laureansari R, Hermans BJM, Pison L, Verheule S, Philippens S, et al.Extended erges classification of paroxysmal and persistent atrial fibril-lation based on P-f-waves. Front Physiol 2022;13:779826. https://doi.org/10.3288/hpysi.2022.779826

52 Gutierrezne,Aorly Flans,Maheshwari A,Rooney MR,Gottesman RF,Mosley THH,et al. Association of abnormal P-wave indices with dementia and cognitive decline over 25 years: ARIC-NICS(the ATHEROSCLEROSIS RISK in Communities Neurocognitive study. J Am Heart Assoc 2019;8:e014553. https://doi.org/10.1161/HA,119:014553

53. Holmqvist F, Platonov PG, McNitt S, Polonsky S, Carlson J, Zareba W, et al.;MADIT II Investigators. Abnormal P-wave morphology is a predictor of atrial fibrillation development and cardiac death in MADIT II patients. Ann Noninvasive Electrocardiol 2010;15:63-72.https://doi.org/10.1111/j.1542-474X.2009.00341.x

54 He. J. Tze G. Korantzopoulos P, Letsas KP, Ali-Hasan-Al-Saegh S,Kamel H, et al. P-wave indices and risk of ischemic stroke: A systematic review and meta-analysis. Stroke 2017;48:2066-2072. https://doi.org/10.1161/STROKEAHA.117/017293

55 Zhu H, Cheng C, Yin H, Li X, Zuo P, Ding J, et al. Automatic multilabel electrocardiogram diagnosis of heart rhythm or conduction abnormalities with deep learning: A cohort study. Lancet Digit Health 2020;2:e348-e357.https://doi.org/10.1016/s2589-7500(20)30107-2

J. Weerts et al.

56. Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M.Clinical outcomes in systematic screening for atrial fibrillation(STROSTEKOPST):A multicentre, parallel group, unmasked, randomised controlled trial. Lancet 2021;398:1498-1506.https://doi.org/10.1016/s0140-6736(21)01637-8

57.Svendsen J,H.Dieredsen ZHOS, Roijberg S, Krieger D,Waff,Cron Borg C,et al.Implantable loop recorder detection of atrial fibrillation to prevent stroke(https://loop study/A.41016/s14016-6736(21)01698-6

58. McIntyre WF, Benz A, Becher N, Healey JS, Granger CB, Rivard L, et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: A study-level meta-analysis of the NOAH-AFNET 6 and ARTESIA trials. Circulation 2023;149:981-988. https://doi.org/10.1161/C/CIRCULATIONAHA.123.067512

59.Guichard JB,Nattel S.Atrial cardiomyopathy:A useful notion in cardiac disease management or a passing leaf? J Am Cardiol 2017:7855-765. https://doi.org/10.1016/j.jacc.2017.06.03761

60. Linz D,Gawalko M,Betz K,Hendriks JM,Lipa LGYH,Zinger V,Tiner,et al.Atrial fibrillation: Epidemiology, screening and digital health. Lonnet Reg Health Eur 2024;37:100786.https://doi.org/10.1016/j.ljape.2023.100786

16. Tzeis S, Gerstenfeld PE, Kalman J, Saad EB, Sephermi Ahno, A. Andrade JG,et al.2024 European Heart, Rhythm Association/Heartthry Society/Acally Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.Euaregeop 2024;6:eueua043.https://doi.org/10.10193/europeu:e043

62. Chou CC, Liu ZY, Chang PC, Liu HT, Wo, HT, Lee, WC et, al. Comparing artificial intelligence-enabled electrocardiogram models in identifying left atrium enlargement and long-term cardiovascular risk. Can J Cardiol 2024:40:585-594.https://doi.org/10.1016/j.cjca.2023.12.025

63. Incard RM, Boniella B, Bering-Sorensen T, Cameli M, Promini M, Lomb Card,et al. Left atrial disease and left atrial reverse remodelling across different stages of hear failure development and progression: A new target for prevention and treatment. Eur J Heart 2022;24:259-975. https://doi.org/10.1002/jefh.2562.

64. Bodagh N, Williams MC, Vickneson K, Gharaviri A, Niederer S, Williams SE.State of the air paper: Carducated computed tomography of the left atrialum fibrillation.J Cardiovasc Comput Tomogr 2023;17:166-176.https://doi.org/10.1016/j.jccst.2023.03.002

65.Nague SF,Smethice On Apcton,CP Byr BD Frd,321 Dokishin,H,Evendras T,et al.Recommendations for the evaluation of left ventricular diastolic function of echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging J. Am Soc Echocardiography 2016:29:277-314.https://doi.org/10.1016/j.ieeh.2016.01.011

6. Badano LP, Kollas TJ, Muruar D, Abraham TP, Aurigema G, Edvarsen T,et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: A consensus document of the EAVIC-IIASEudity Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging 2018;19:591-600. https://doi.org/10.1093/ehjci/042021.

67. Thomas L. Muru, D. Pescuai BP, Sigaes, Rosca M. Pedrizetti S, et al.Evaluation of left atrial size and function: Relevance for clinical practice. J Am Soc Echocardiogr 2020:33:94-952.https://doi.org/10.1016/j.ieeh:2020.03.021

68. Inoue K, Khan FH, Renme EW, Ohtne Q, Garia-couberido E, Chretir M, et al.Determinants of left atrial reservoir and pump strain and use of atrial strain for evaluation of left ventricular filling pressure. Eur Heart J Cardovacs imaging 2021:63:71.https://doi.org/10.1093/ehjciae415

69.Cameli M,Sparla S,Losito M,Righini FM,Menci D,Lisi M,et al. Correlation of left atrial strain and Doppler measurements with invasive measurement of left ventricular end-diastolic pressure in patients stratified for different values of ejection fraction. Echocardiography 2016:33:398-405. https://doi.org/10.1111/echo/13094

70. Kurt M, Tanboga IH, Aksakal E, Kaya A, Isik, Ekin M, et al. Relation of left ventricular end-diastolic pressure and N-terminal pro-brainriatic peptide level with left atrial deformation parameters. Eur Heart J Cardovacos Imaging 2012;13:524-530.https://doi.org/10.1093/ejchocar/2873

11. lanoneaccon G, Granszi F, Debono MG, Camili M, Lilo R, Celle A, F. et al. Left atrial strain analysis improves left ventricular filling pressures non-invasive estimation in the acute phase of Takotsubo syndrome. Eur Heart J Cardiovasc Imaging 2023:2499-707.https://doi.org/10.1093/ehjci/jeo0454

72. Smisetho EM, Morris DA, Cardim N, Cikes M, Delgado V, Donal et al. Multi-modality imaging in patients with heart failure and pressure ejection fraction:An expert consensus document of the European Association of Carducosu-lar Imaging. Eur Heart J Cardiovasc Imaging 2022:23:e34-e61.https://doi.org/10.1093/ebjia154

73. Bandera F, Mollo A, Frigelli M, Guglielle G, Vennorva N, Pastore MC, et al.Cardiac imaging for the assessment of left atrial mechanics across heart failure

stages.Frontos Cardiovasm Med 2021:8:750139.https://doi.org/10.3389/fcmv.2021.7509-1398

74. Modin D, Biering-Senresen S, Mogelvang R, Alhakak AS, Jensen JS,Biering-Senresen T. Prognostic value of left atrial strain in predicting car-diovascular morbidity and mortality in the general population. Eur Heart J Cardiovasc Imaging 2019;20:804-815.https://doi.org/10.1093/ehjcijey/1081

75. Huber MP, Pandie JA, Jensen PN, Wiggins KL, Patel RB, Freed BH, et al. Left atrial strain and the risk of atrial arrhythmias from extended ambulatory cardiac monitoring: MESA J,Aim Heart Assoc 2022;11:e026875.https://doi.org/10.1161/JA:122.026875.

76. Mannina C, Ito K, Jin Z, Yoshida Y, Matsumoto K, Shames S, et al. Association of left atrial strain with ischemic stroke risk in older adults. JAMA Cardiol 2023:8:317-325. https://doi.org/10.1001/jamacardio.2022.5449

77. Park JH, Hwang IC, Park JJ, Park JB, Cho GY. Left atrial strain to predict stroke in patients with acute heart failure and sinus rhythm. J Am Heart Assoc 2021;10:e020414.https://doi.org/10.1161/JAHA.120.020414

78. Khan HR,Yakupogluu K,Yrali-Jahans I,Haldar S,Bahrami T,Clague J,et al.;CASA AF Investigators. Left atrial function predicts atrial arrhythmia recurrence fol-lowing ablation of long-standing persistent atrial fibrillation. Circ Cardiovasc Imag-ing 2023;16:e015325. https://doi.org/10.1161/CIRCIMAGING.123.015352

79.Sugimoto T, Robinet,S. Dulgheru R, Bernard A, lardi F, Contu et al. Echocar-diographic reference ranges for normal left atrial function parameters: Results from the EACN NORERE study. Eur Heart J Cardiovasc Imaging 2018;19:630-638.

80.Singh A, Carvalino Sugilane C, Miyoshi T, Prado AD, Addeta K, Bellino M,et al.; WASE Investigators. Normal values of left atrial size and function and the impact of age of Results of the World Alliance Societies of Echocardiography study.J Am Soc Echocardiogr 2022;35:154-164.e3.https://doi.org/10.1016/j.echo.2021.08.008

81.Nielsen AB,Skaupar K,G Hauser R,Johansen ND,Lassen MCH,Jensen GB,et al.values and reference ranges for left atrial strain by speckle-tracking echocardiography. The echocardiography: Copenhagen City Heart Study. Eur Heart J Cardiovasc Imaging 2021:23:421-51.https://doi.org/10.1093/ehjci/jeab201

82.Mohseni-Badabalad R, Mirjalili T, Jalali A, Davarpasand T, Hosseinsabet A. A systematic review and meta-analysis of the normal reference value of the longi-tudinal left atrial strain by three dimensional speckle tracking echocardiography.Sc Rep 2022;12:4395.https://doi.org/10.1038/s41598-022-08379-7

83.Inciardi RM,Claggett B,Minamisawa M, Shin SH, Selvaraj S, Goncalves A, et al.Association of left atrial structure and function with heart failure in older adults;Jan Cell Cardiol 2022;79:1549-1561.https://doi.org/10.1016/j.jacc.2022.01.035

84. Kawakami H, Ramkumar S, Nolan M, Wright L, Yang H, Negishi K, et al.Left atrial mechanical dispersion assessed by strain echocardiography as an independent predictor of new-onset atrial fibrillation: A case-control study.J Am Soc Echocardiology 2019;32:1268-1276.e3. https://doi.org/10.1016/j.echo 2019.06.002

85.Kim D,Seo JH,Choi KH, Lee SH,Choi JO,Jeon ES,et al. Prognostic implications of left atrial stiffness index in heart failure patients with preserved ejection fraction.JACC Cardiovasc Imaging 2023;16:435-445.https://doi.org/10.1016/j.cms.222.1100

86. Luis SA, Chan J, Pelliksa PA. Echocardiographic assessment of left ventric-ular systolic function: An overview of contemporary techniques, including speckle-tracking echocardiography, Mayo Clin Proc 2019;94:125-138. https://doi.org/10.1016/j.moycp.2018.07.017

87. Nguyen J, Weber J, Buhs M, Bulyala RR, Wang L, Cao JJ. Comparing left atrial indices by CMR in association with left ventricular diastolic dysfunction and adverse clinical outcomes. Sci Rep 2021;11:21331.https://doi.org/10.1038/s41598-021-00596-w

88.Truong VT,Palmer,C.Wolking S,Sheets B,Young M,Ngo TNM,et al.Normal left atrial strain and strain rate using cardiac magnetic resonance feature tracking in healthy volunteers. Eur Heart J Cardiovasc Imaging 2020:21:446-453. https://doi.org/10.1093/ehjci/je157

89. Qu YY, Buckert D, Ma, GS, Rasche V. Quantitative assessment of left and right atrial strains using cardiovascular magnetic resonance based tissue tracking.Front Cardiovasc Med 2021:8:690240.https://doi.org/10.3389/fcvm.2021.690240

90 Eckstein J,Korperin H, Paluszkiewicz L, Burchert W, Piran M. Multi-parametric analyses to investigate dependencies of normal left atrial strain by cardiovascular magnetic resonance features capture tracking. Sci Rep 2022:12:12323. https://doi.org/10.1038/s41598-022-16143-0

91. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong An Erande L, et al.Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.e14.https://doi.org/10.1016/j.echo.2014.10.003

$$\text{ ESC/HFA consensus statement on a trial cardiomyopathy}$$

92. Maceira AM, Cosin-Sales J, Roughton M, Prasad SK, PenneJl DJ. Reference left aial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:65. https://doi.org/10.1186/1532-429x-12-65.

3. Stolzmann P, Scheffel H, Leschek S, Schertler T, Frauenfelder T, Kaufmann PA,et al.Reference values for quantitative left ventricular and left atrial mea-surements in cardiac computed tomography. Eur Redol 2008;18:1625-1634.https://doi.org/10.1007/s00330-008-0939-4

94. Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ,Jerosher-Hoold M, et al. Reference ranges("normal values") for cardiovascular magnetic resonance(CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson 2020;22:87.https://doi.org/10.1186/s12968-020-00683-3

5U. FYn, Devereux RB, Roman MJ, Meng J, Jow VM, Jacobs A, et al. Cardiac chamber volumes, function, and mass as determined by 64-multidetector row computed tomography: Mean values among healthy adults free of hypertension and obesity. JACC Cardiovasc Imaging 2008;1:782-786. https://doi.org/10.1016/j.jcmg.2008.04.015

96.Tzang TS,Abhayaarmpa W,Barnes ME, Miyasaka K, Gersh BJ,Bayden KR,et al.Prediction of cardiovascular outcomes with left atrial size: Is volume superior to area or diameter? J Am Coll Cardiol 2006;47:1018-1023. https://doi.org/10.1016/j.jacc.2005.08:07.5

97. Aquaro GD, Camara G, Monti, L. Lombardi M, Pepe A, Castelletti S, et al.;Workin Group"Applicazioni della Risonanza Magnosa" of the Italian Society of Cardiology. Reference values of cardiac values of volumes, dimensions, and new functional parameters by MR: A multicenter, multivender study.J Magn Reson Imaging 2017:45:1055-1067. https://doi.org/10.1002/jm25450

98. Yafasov M, Olsen FJ, Skaarup KG, Lassen MCH, Johansen ND, Lindgren FL,98. et al. Normal values for left atrial strain, volume, and function derived from 3D echocardiography: The Copenihen City Heart Study. Eur. Heart J Tardoson Imaging 2024;25:602-612.https://doi.org/10.1093/ehcije/ae018

99. Scattiae A, Baritussio A, Bucciarelli-Ducci C. Strain imaging using cardiac magnetic resonance. Heart Refv 2017:22:456-475. https://doi.org/10.1007/s10741-017-9621-8

100. Keller K,Sinning C,Schulz A,Jünger C,Schmitt VH,Hahad O,Lear right atrio size in the general population. Sci Rep 2021;11:22523.https://doi.org/10.1038/s41598-021-01968-y

101.Bayes-Gaussi,A Bbal,Folune Z.Janufe Z.Janufe J,Rossigin P,et al.Thusion in prefronting to clinical heart in clinical heart fraction section fraction: A mechanistic approach. J Clin Med 2020:9:1101.https://doi.org/10.3390/90941110

102. Sade LE, Frales FF, Pontone G, Gerber BLM, Muraui D, Devsdersen T, et al.The role of modality-imaging ability for the assessment of left atrium and left atrial appendage. A clinical consensus statement of the European Association of Cardiovascular Imaging(EACVI), European Heart Rhythm Association(EHRA)of the European Society of Cardiology(ESC). Eur Heart J Cordovasc Imaging of Section 25;26:385-413.https://doi.org/10.1093/ehjcia/jeaf014

103. Shah AM, Clagggett B, Sweitzer NK, Shah SK, Anand IS, OsA'Meera E, et al. Car-duc structure and function and prognosis in heart failure with preserved ejec-tion fraction: Findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antago-nis(TOPCAT) Trial. Exc Heart Fall 2014:740-751. https://doi.org/10.1161/CRCIRHEARTFAILURE 114.001583

Froehlich L Meyre, Aesbacher S, Blum S, Djodic, Kuehe M, et al Left arial dimension and cardiovascular outcomes in patients with and without trial fibrillation: A systematic review and meta-analysis. Heart 2019:1085:1881-1981.https://doi.org/10.1136/hearintjal-2019-315174

105. Gulati A, Ismail F, Jabbour A, Ismail N, Marorji, K Ali, A et al. Clinical and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non-ischaemic dilated cardiomyopathy. Eur J Heart Fall 2013;15:660-670.https://doi.org/10.1003/ouref/htf019

106.Toufman M,Kazemi M,Bolazadeh N.The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion.J Cardiovasc Thorac Res 2017;9:54-59.https://doi.org/10.1517/jcvr.2017.08

17. Incardi RM, Pagnes M, Lombard CM, Alker SD,Cleid J.Gickstein K, et al.Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. Eur J Heart Fail 2022:24:2131-2139. https://doi.org/10.1002/ejf.1893

Pascual-Figal DA, Zamorano JL, Domingo M, Morillas H, Nufuěz, J. Cobo Marcos M, et al; DAPA-MODA Study Investigators. Impact of dagapflinoz lacardic remodelling in patients with chronic heart failure: The DAPA-HODA study.Eur J Heart Fail 2023:25:1352-1360.https://doi.org/10.1002/ejhf.2884

10. Laukkanen JA, Kurl S, Enraen J, Huttunen S, Malen Solen J, Left atrial size and the risk of cardiovascular death in middle-aged men. Arch Intern Med 2005;165:1788-1793.https://doi.org/10.1001/archite.165.15.1788

110. Gupta,Satulevicus SA,Yers CR,Berry JD,Patel PC,Markham DW,et al Left atrial structure and function and clinical outcomes in the general population.Eur Heart J 2013:34:278-285.https://doi.org/10.1093/eurheart/ehs188

111.Hammerley DJ, Mukhopadhyay S, Chen X, Cheng X, Jones R, Mach L, et al.Compressive diagnostic importance of measures of left atrial structure and function in non-ischaemic dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging 2024:256:1566-1574.https://doi.org/10.1093/ehjci/ae080

112.Shin SH,Clagglet B,Clardiarii RM,Santos ABS,Shah SJ,Zile MR,et al.Prognostic value of minimal left atrial volume in heart failure with preserved ejection fraction.J Am Heart Assoc 2021:10:e019545.https://doi.org/10.1161/JAHA.120.019545

113. Fatama K. Barnes ME, Bailey KR, Abhayarana WP, Cha S, Seward JB, et al.Minimum vs. maximum left atrial volume for prediction of first atrial fibrilla-tion or flutter in an elderly cohort: A prospective study. Eur J Echocardiogr 2009;10:382-286.https://doi.org/10.1093/ejechocard/jen235

114. Schotten U, Goette A, Verheule S. Translation of pathophysiological mechanisms of atrial fibrosis into new diagnostic and therapeutic approaches. Nat Rev Cardiol 2025:22:225-240.https://doi.org/10.1038/s41569-024-01088-w

115. Weber K, Pick R, Jallil JE, Janicki JS, Carroll EP. Patterns of myocardial fibrosis. J Mol Cell Cardiol 1989;21:121-131. https://doi.org/10.1016/0022-288(89)7078-59.

116. Smishton OA,Baron T,Marino PN,Marrowt CH, FlashkampfFA. Imaging of the left atrial: Pathophysiology insights and clinical utility. Eur Heart J Cardiovasc Imaging 2021;23:2-13. https://doi.org/10.1093/ehjci/jeab191

117. Hopman B, Lhagirath P, Mulder MJ, Egghink IN, van Rossum AC, Allaart CP,et al. Quantification of left atrial fibrosis by 3D late gadolinium-enhanced cardiac magnetic resonance in imaging in patients with atrial fibrillation: Impact of different analysis methods.Eur Heart J Cardiovasc Imaging 2022:23:1182-1190.https://doi.org/10.1093/ehci/jejab245

118 Eichenla M, Muedu Eenborn B, Minners J, Figueras IVRM, Forcada BR,Colomerav,et al. Comparison of various late gadolinium enhancement mag-netic resonance imaging methods with high-definition voltage and activation mapping for detection of atrial cardiomyopathy. Europoe 2022:24:1102-1111.https://doi.org/10.1093/europace/euac010

11. Quail M, Greunseich K, Baldassarre LA, Mojibian H, Marieb MA, Cornfeld D,et al.Prognostic and functional implications of left atrial late gadolinium enhance-ment cardiovascular magnetic resonance.J Cardiovasc Magn Reson 2019;21:2.https://doi.org/10.1186/6/12968-018-0514-3

120. Tandon K, Tirschwell D, Longstreht WT Jr, Smith B, Akoum N. Embolic stroke of undesired source correlates to atrial fibrosis without atrial fibrillation. Neurology 2019;93:e381-e387.https://doi.org/10.1212/wnl.

1211. Nairn D,Eichenla Hu, Muller-Edenborn B, Huang T, Lehrmann H, Nagel C,et al. Differences in atrial substrate localization using late gadolinium enhancement-magnetic resonance imaging, electrogram voltage, and con-duction velocity: A cohort study using a consistent anatomical reference frame in patients with persistent atrial fibrillation. Europace 2023;25:eudau278.https://doi.org/10.1093/europace/euad278

121. Lisi M, Mandoli GE, Cammi M, Pastore MC, Righini FM, Benfari G, et al. Left atrial strain by speckle tracking predicts atrial fibrosis in patients undergoing heart transpiration. Eur Heart J Cardiovasc Imaging 2022;23:829-835.https://doi.org/10.1093/ehci/jeab/106

12.Camelli M, Lui M, Righini FM, Massoni A, Natali BM, Focardi M, et al. Useful of strain of deformation analysis to predict left atrial fibrosis and endocardial thickness in patients undergoing mitral valve operations for severe mitral regurgi-giation secondary to mitral valve prolapse. Am J Cardiol 2013;111:595-601.https://doi.org/10.1002/jacm.1012.10.049

124. Farrag NA, Thornhill RE, Prato FS, Skanes AC, Sullivan R, Sebben D, et al.Assessment of left atrial fibrils progression in canines following rapid ven-tricular pacing using BD late gadolinium enhanced CMR images. PLoS One 2022;17:e06952.https://doi.org/10.1371/journal.pone.0269592

125. Marrouche NF, Wilberer D, Hindricks G, Jais P, Akoum N, Marchlinski F,et al. Association of atrial tissue fibrosis identified by delayed enhance-ment MRI and atrial fibrillation catheter ablation: The DECAFA study. JAMA 2014.31:498-506.https://doi.org/10.1001/jama.2014.3

126. Vyas, Van Hunter, RJer, Honghi MP, Finlay MC. Inflammation and adiposity: New frontiers in atrial fibrillation. Europace 2020:22:1609-1618. https://doi.org/10.1002/europae/eua214

127. Müller P, Weis B, Lemmelans N, Mügge A, Eckardt L, Crijns H, et al.Echocardiography-derived total atrial conduction time(PA-TDI duration): Risk stratification and guidance in atrial fibrillation management. Clin Res Cardiol 2021:110:1734-1742.https://doi.org/10.1007/s00392-021-01917-9

128. Karakis P, Theofisil, Vplachakis PK, Korantzopoulos P, Patoulias D, Anto-niadis AP, et al. Atrial Fibrillation: Mechanistic insights, diagnostic

J. Weerts et al.

challenges, and emerging therapeutic targets. Int J Mol Sci 2024;26:209.https://doi.org/10.3390/jims262010209

129. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Combridged inertia. Red myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263-271.https://doi.org/10.1016/j.jacc.2013.02.092

130. Deichai W, Rachever I, Redemnian, Corroblichen in heart failure with preserved ejection fraction. Herz 2022:47:301-307. https://doi.org/10.1007/s00059-022-05123-9

131. Jani BD, NJichol, Bl McQueenie R, Connelly PT, Hanlon H, Gallakchi E, KL et al.Mortimubility and co-morbidity in atrial fibrillation and effects on survival:Findings from UK Biobank cohort. Euro2018:20f329-f336. https://doi.org/10.1093/europeu/eux322.

132. Molnár A, Santa A, Pasztor DT, Merkely B. Atrial cardiomyopathy in valu-lar heart disease: From molecular biology to clinical perspectives. Cells 2023;12:1796.https://doi.org/10.3390/cells12131796.

133. Hahn RT, Badano LP, Bartko P, Murpean, D.; Maisano F, Zamorano JL, et al.Tricuspid regurgitation: Recent advances in understanding pathophysiology,severity growth and outcome. Eur Heart J Cardiovasc Imaging 2022:23:913-929.https://doi.org/10.1093/ehjcij/jeuc009

134. Defern S. Rerrand PB, Verbrugpe FH, Verbrugte A. Røms, Haar D. Fomas J.D. et al.Atrial natalrial mit regurgitation: JACC review topic of the week. J Am Coll Cardiol 2019;73:2465-2476.https://doi.org/10.1016/j.jacc.2019.02.061

13. Johnson LS, Platonov PG, Conen D, Kennack C, Jucci J, Healey JS, et al.Markers of atrial myopathy in the general population: Prevalence, predictors,and inter-relations./CCAC Clin Electrophysiol.2023:9:2240-2249.https://doi.org/10.1016/j.jacep.2023.07.012

136. Obatak M, Reddy YNVP, Pisarlu S, Melovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6-19.https://doi.org/10.1161/C/CIRCULATIONAHA.116.026807

137. Adamo M. Clochon C, Omelger M, Bayes-Genis A. Abdhamel M. Anker SD,et al. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus state-ment of the Heart Failure Association(HFA) and the European Association of Percutaneous Cardiovascular Interventions(EAPCl) of the Esc. Eur J Heart Fail 2024;26:18-33.https://doi.org/10.1002/efj.3106

19. Rofesjo P, RFosch,Schober AR,Fengler K, Schotter F,Bombace St,et al. Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction. Eur. Heart Fall 2024;26:1025-1035.https://doi.org/10.1002/ehjf.3195

139. van Mourik MJW, Artola Arita Lya, Von Lumens, J. De With RR, van Melle JP,et al. Association between comorbidities and left and rights arrial dysfunction in patients with paroxysmal atrial fibrillation: Analysis of AF-RISK. Int J Cardiol 2022:36:29-35.https://doi.org/10.1016/j.icj.2022.05.044

10. Kotaeche D,Lam,Cus,Van Veldhusen DJ,Gelder Jic,Ao years, Rensia M. Heart failure with preserved ejection fraction and atrial fibrillation: Vicus twins.J Am Col Calord 2016:68:2172-228. https://doi.org/10.1016/j.jacc.2016.08.048

141. Reddy NVY, Carter Be, Okobata M, Redfield M, Borlaug BA. A simple,evidence-based approach to help guide diagnosis of heart failure with pre-served ejection fraction. Circulation 2018;138:861:870.https://doi.org/10.1011/c.8611.1161/C/C/CULATIONAHA.118.034646

142.Bayes-Genis A, Docherty KF,Petrie MC,JanuzziJ,MLuer C,Anderson L,et al.Practical algorithms for early diagnosis of heart failure and heart stress using NT-probNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart fail 2023:1591-1989. http://doi.org/10.1002/ejh.3036

143. Kamel H, Longstrech WT Jr,Tirschwell DL,Kronra RA, Marshall RS, Brod-erick J, et: ARCADA Investigators. Apibolaen to prevent recurrence after cryptogenic stroke in patients with atrial cardiography: The ARCADIA random-ized clinical trial. JAMA 2024:331:573-581. https://doi.org/10.1001/jama.20237188

144.Tripathi R, Wang D, Sullivan R, Fan TH, Gladysheva IP, Reed GL. Depressed corin levels indicate early systolic dysfunction before increases of atrial nari-uretic peptide/B-type natriuretic peptide and heart failure development. Hyper-tension 2016:67:362-367.https://doi.org/10.1161/HYPERTENSIONAHA.115.06300

15. Lee,Ru X,Bane J,Feel Klein,BENLton,P.Dries D. Regulated insotinol/requiring protein 1-dependent decay as a mechanism of corin RNA and protein deficiency in advanced human systolic heart failure. J Am Heart Assoc 2014:3e001104.https://doi.org/10.1161/j.AHA.114.001104

146. Matsumoto S, Nakazawa G, Ohnoy,I Ishiiar M, Sakai K, Nakamura N, et al.Efficacy of exogenous atrial natureric peptide and patients with heart failure with preserved ejection fraction: Deficiency of atrial natriure peptide and

replacement therapy. ESC Heart Fail 2020:7:4172-4181.https://doi.org/10.1002/ehf2.13042

147. Lebuogu UN, Gladyheva IP, Houng AK, Reed GL. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial nitrate nepeptide. Circ Heart Fail 2011:4:114-120. https://doi.org/10.1161/CIRCHEARTFAILURE.109.895581

148.Gladyheva P, Sullivan RD, Reed GL. Falling corin and ANP activity levels accelerate development of heart failure and cardiac fibrosis. Front Cardiovasc Med 2023;10:1120487. https://doi.org/10.3389/fcvm.2023.1120487

149. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, et al.Association of atrial natriuretic peptide and type A natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension.J Am Coll Cardiol 2006;48:499-505.https://doi.org/10.1016/j.jacc.2005.12.081

150.Forte M, Marchiti S, Di Nonno F, Stanzione R, Schronei L, Cotugno M, et al.NPRA/atrial natriuretic peptide is an extracellular modulator of autophagy in the heart. Autophagy 2023;19:1087-1999.https://doi.org/10.1080/15548627.2022

151. Rafrais F,Sorte F,MaGol,Ranieri D,Marchiti S,Magri D,et al.Atrial natriuretic peptide stimulates automophagy/mitophagy and improves mitochondrial function in chronic heart failure. Cell Mol Life Sci 2023;80:134.https://doi.org/10.1007/s0018-023-04777.w

152. Hua R, MacLeod, SL, Molina I, Mogtadaei M, Jansen HJ, Bogachev O, et al. Effects of wild-type and mutant forms of atrial natriuretic peptide on atrial electrophys-iology and arrhythmogenesis. Circ Arrhythm Electrophysiol 2015:8:1240-1254.https://doi.org/10.1161/circcop.115.002896

153. Vergro G,Amo A,Rapezzi C,Castiglione V,Fabiani I, Pucci A,et al.Arialriyosis: mechanisms and clinical manifestations. Eur J Heart Fail 2022:24:2019-2028.https://doi.org/10.1002/ejhf.2650

154.Yang,ZSub,Taiu,Kim,Kurphy MB,Dougherty OP,Christopher IL,et al.Natriuretic peptide oligomers cause prorrathmic metabolic and electrophysi-tological effects in atrial myocytes. Circ Arrhythm Electrophysiol 2022;15:e010636.https://doi.org/10.1161/circep.121.010636

15.Schweizer J,Arnold J,Knigol IR,Bicvic A,Westphal LP,Schütz V,et al.Measure-ment of midregional pro-atrial natriuretic peptide to discover atrial fibrillation in patients with ischemic stroke.J Am Coll Cardiol 2022;79:1368-1381.https://doi.org/10.1016/j.jacc.2022.01.042

156.Cui K,Huang W,Fan J,Lie H.Lidregional pro-atrial natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction. Medicine(Baltone 2019;8:97:12277.https://doi.org/10.1097/md.000000000012277

157.Putko BN,Savu A,Kaul P,Ezekowitz J,Dyck JR,Anderson TJ,et al. Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure. Eur Heart J Cardiovasc Imaging 2021:22:220-228. https://doi.org/10.1093/ehcij/ea041

158. Sinner MF, von Falkenhausen AS. A specific new biomarker for atrial fibril-lation and its sequelae; Eur Heart J 2023;44:219-220. https://doi.org/10.1093/ejci/ae041

19. Bouvard C,Tu L,Rossi M, Desroches-Castan A, Berrehem N, Helfer E,et al. Different cardiovascular and pulmonary phenotypes for single- and double-knock-out moiré deficient in BMP9 and BMP10. Cardiovasc Res 2021:1180-1805.https://doi.org/10.1093/cvr/cvab187

160.Hijazi Z,Benzn AL, Lindblack J,Alexander JH,Connolly SJ, Eikelboom JW,et al.Bone morphogenetic protein 10: A novel risk marker of ischaemic stroke in patients with atrial fibrillation. Eur Heart J 2023;44:208-218. https://doi.org/10.1093/eurheart/ehac632

161.Meyre PB, Aschbacher S, Blum S, Vollin G, Kastner PM, Hennings E,et al. Biomarkers associated with rhythm status after cardioversion in patients with atrial fibrillation. Sci Rep 2022;12:1680. https://doi.org/10.1038/s41598-022-05769-9

16. Gkarmoris KI, Lindback J, Alexander JH, Granger CB, Kastner P, Lopes RD,et al. Repeated measurement of the novel atrial biomarker BMP10(bone rntimal B, Repeel protein, 10) refines risk stratification in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial. J Am Heart Assoc 2024:13-033720. https://doi.org/10.1061/JAHA.123.033720

13. Ehrenn E, Blum S, Blachacher S, Cosovsky M, Knecht S, Eken C, et al.;Swiss-AF Investigators. Bone morphogenetic protein 10- a novel biomarker to predict adverse outcomes in patients with atrial fibrillation. J Am Heart Assoc 2023;12:0e28255. https://doi.org/10.1161/JAHA.122.028255

164. de Bakker M, Petersen TB, Akkerhuis KM, Harakalova M, Umans VA, Ger-mans T,et al. Sex-based differences in cardiovascular proteomic profiles and their associations with adverse outcomes in patients with chronic heart failure.Biol SerDiff 2023;14:29.https://doi.org/10.1186/s13293-023-00516-9

15 Winters, J. Kawczynski JM, Gilbers MD, Isaacs A, Zeemering S, Bidar E, et al.Circulating BMP10 level maps associate with late postoperative atrial fibrillation

ESC/HFA consensus statement on atrial cardiomyopathy

and left atrial endomys fibrosis. JACC Clin Electrophysiol 2024;10:1326-1340.https://doi.org/10.1016/j.xjace.2024.03.003

166. Liu L, Liang Y, Lan QG, Chen JZ, Wang R, Zhao JH, et al. Bone morphogenetic protein 10 and atrial fibrillation. JC) Heart Vexi 2024:451:101376. https://doi.org/10.1016/j.ijcha.2024.101376

167. Chua W, Cardoso VR, Guasch E, Sinner MF, Al-Taie C, Brady P, et al.An angiopieto 2, FGF3, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions. Sci Rep 2023;13:16743.https://doi.org/10.1038/s41598-023-42331-7

168. Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation.JACC Clin Electrophysiol 2017;3:425-435.https://doi.org/10.1016/j.jacep.2017.03.002

169. Hatem SN,Sanders S.P. Epideric adipical tissue and atrial fibrillation. Cardiovasc Res 2014;102:205-213.https://doi.org/10.1093/cvrvu045

170. Harada S,Nattel S. Implications of inflammation and fibrosis in atrial fibrillation pathophysiology. Card Electrophysiol Clin 2021;13:25-35. https://doi.org/10.1016/j.cce.2020.11.002

177. Schonen Guo, Vrehle S, Kirinca H, Pongelte B, Gaope et A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev 2011;91:265-325.https://doi.org/10.1152/physrev.00031.2009

178. Verheue S, Schotten U. Electrophysiological consequences of cardiac fibrosis.Cells 2021;10:3220.https://doi.org/10.3390/cells11013220

175. Luede M, Winkler T, Heisen FA, Rühmann M, Mc Spehmann ME, Bajrovic A,et al. Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail 2017;4:282-290.https://doi.org/10.1002/ehf.212155

174. Sun Z, Zhou D, Xie X, Wang S, Zhou Z, Zhao, W et al. Cross-talk between macrophages and atrial myocytes in atrial fibrillation. Basic Res Cardiol 2016;111:63.https://doi.org/10.1007/s00395-016-0584-z

158. Leal A, O'Donnel JA, Nakai ME, Nanayakkara S, Vizi D, Carter K, et al.The gutiome microbiome of heart failure with preserved ejection fraction.J Am Heart Assoc.2021;10:0026545.https://doi.org/10.1161/JAHA.120.12020654

Zuo K,Yin,Xin,Li K,Zhang,Wang J,Piao J,Jet al. Different types of atrial fib-rillation share patterns of gut microbiobasis. dysmph. Smpio. 2020:5:e0007-210.https://doi.org/10.1128/msphere0007-210.

177. Heijman, Muna Y, Leveva T, Molina CE, Sutano H, Tekook M, A, et al. A myocyte NLRP3/CaMKII nexus forms a substrate for postoperative atrial fib-cration. Rec Res 2020:127:1063-1055.https://doi.org/10.1161/CIRCRESHAHA.120.316710

178.Zhang Y,Zhang S,Li B,Luo Y,Gong Y,Jin X,et al.Gut microbysis obprosia-motes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inamplasome. Cardiovasc Res 2022;118:785-797.https://doi.org/10.1093/crv/cvab114

179. Dobrev D, Heijman J, Ririn L, N. Nattel S. Inflammatory signalling in atrial cardiomyocytes: A novel unifying principle in atrial fibrillation pathophysiology.Nat Rev Cardiol 2023:20:145-167. https://doi.org/10.1038/s41569-022-00759

8018.Song J.,Navarro-Garcia JA, Wu J, Saljic A, Tuah a,Li L, et al. Chronic density disease promotes atrial fibrillation via inflammasome pathway activation. J Clin Invest 2023;133:e167517.https://doi.org/10.1172/CJ167517

181. Hulmans+McSchio MJ. Lee H.Ju, Babap A. Iwamoto Y., Vinegoni C, et al.Recuted macrophages elicit atrial fibrillation. Science 2023:381:231-239.https://doi.org/10.1126/science.abq3061

18. Li,LaCarfa,Yan,Yu,Abaha,Ti,Wang,S.Jong,Tu.iseFrobast-restricted inflammas homeodynamic activation promotes atrial fibrillation and heart failure with diastolic dysfunction. JACC Basic Transl Basic 2025;10:10144.https://doi.org/10.1016/j.jacbs.2025.02.004

18. Collins RC, Robertson AA, Chj Higgins, Higgins Mac, Suflo-Planillo R, Resilla MC,et al et A small-molecule inhibitor of the NLR3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015;21:248-255.https://doi.org/10.1038/nm./nm.3806

14. Mangan MSJ Oilana EJ. Rough, VR, Seidel HM, Glick GD, Laze E-Target-ing the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 2018;17:588-606.https://doi.org/10.1038/nrd.2018.97

15. Neetsa, Quoen LA.Inflammasone inhibition: Putting out the fire. Cell Metab 2015;21:513-514.https://doi.org/10.1016/j.cmet.2015.03.012

186 Meska-Tuor R, Zhang R, de Couto de G, Valle's Sanchez L, Schen Rogers, R et al.Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction. Heart Rhythm 2020:17:1025-1033.https://doi.org/10.1016/jhrm.2020.02.007

187.Yao,CVeale T,Scott L J Jr,Cao S,Li L,Chen G,et al.Enhanced car-diomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circu-lation 2018;138:2227-2242.https://doi.org/10.1161/CIRCULATIONAHA.1183.035202

188. Man SM, Kanneganic T.D. Converging roles of caspases in inflammasome activa-tion, cell death and innate immunity.Nat Rev Immunol 2016;16:7-21.https://doi.org/10.1038/nri.2015.7

1997. Tan X,Zhang N,Korantzopoulos P, Bazoukis G, Letsas KP, Tse G, et al.Efficacy and safety of colchicine for atrial fibrillation prevention: An updated meta-analysis of randomized controlled trials. Int J Cardiol 2024:406:132068.https://doi.org/10.1016/j.ijcard.2024.132068

190. Conen D, Ke Wang M, Popova E, Chan MTV, Landoni G, Cata JP, et al;COP-AF Investigators. Effect of colchicine on perioperative atrial fibrilla-tion and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery(COP-AF): An international randomised trial. Lancet 2023:402:1627-1635.https://doi.org/10.1016/s0140-6736(23)01689-6

191. Nidorf SM, Fiolet ALT, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ,et al; LoCo2-Toi43.1995| Investigators. Colchicine in patients with chronic coro-nary diseases. N Engl J Med 2020;383:1838-1847.https://doi.org/10.1056/IN/Emao2021372

1921.Esinear D,Caldwell,JL,Trafford AW,Hutchings DC.The control of diastolic calcium in the heart: Basic mechanisms and functional implications. Circ Res 2020;126:395-412.https://doi.org/10.1161/CIRCRESAHA.119.315891

193 Nattel S, Heijman J, Zhou L, Doubre D. Molecular basis of atrial fib-rillation pathophysiology and therapy: A translational perspective. Circ Res 2020;127-51: https://doi.org/10.1161/CIRCRESAHA.120.316363

194. Grammaska Davidou N,Dobrev S,Beneke K, Reinhardt F, Peca S, Jacquet E,et al. Phosphodisterio have 26 governs cAMP/PKA-dependent reduction of L-type calcium current in human atrial fibrillation: A novel arrhythmogenic mechanism.Eur Heart J 2023;44:243-2494.https://doi.org/10.1093/eurheart/ehad086

1951. Heijman J, Zhou X. Morotti S, Molina CE, Abu-Taha, IH, Tekook M, et al.Enhanced Ca2+-dependent SK-channel gating and membrane trafficking in human atrial fibrillation. Circ Res 2023;132:e116-e133.https://doi.org/10.1161/CIRCRESAHA.1223.21858

96. Pabel S,Krenier M,Stelle A, Bleander F, Paulus M,Sieme M,et al.Effects of atrial fibrillation on the human ventricle. Circ Res 2022;133:994-1010.https://doi.org/10.1161/CIRCRESHA12.321858

197. Reddy VNN,Borugla B,Aerch B.Jh Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction. Cir-culation 2022:146:339-357.https://doi.org/10.1161/CIRCULATIONAHA.122.05444

198. Zile MA, Trayanova NA. Increased thin filament activation enhances alter-nans in human chronic atrial fibrillation. Am J Physiol Heart Circ Physiol 2018;135:14163-14162.https://doi.org/10.1152/ajpheart.00658.2017

199. Brouwer WP, van Dijk SJ, Stenen GJ, van Rossum AC, Velden J, Germans T. Vorgenans T.The development of familial hypertrophic cardiomyopathy: From mutation to bedside. Eur J J Kstern 2011;41:568-578. https://doi.org/10.1111/j.1365-2362.2010.02439.x

200.Natel S. Close connections between contraction and rhythm: A new genetic cause of atrial fibrillation/cardiomyopathy and what it can teach us. Eur Heart J 2017:38:35-37.https://doi.org/10.1093/eurheartj/ehw457

2011.Molina CE,Au-BaTa,Hu L,Chronic K,Elman M, Nattel S,et al.Profibrotic, electrical, and calcium-handling remodeling of the atria in heart failure patients with and without atrial fibrillation. Front Physiol 2018;9:1383.https://doi.org/10.1389/fphys.2018.01383

2020.Voigt N,Li N,Wang Q,Wang W,Trafford AW,Abu-Taha I,et al.Enhanced sarcoplasmic curriculum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed depolarizations in patients with chronic atrial fibrillation.Circulation 2012:125:2059-2070.https://doi.org/10.1161/CIRCULATIONAHA.111.1067306

2031.Frak M,Le Shen X,Roe AT,Hou Y,Manfra O,et al.Etiology-dependent impairment of diastolic cardiomyocyte calcium homeostasis in heart failure with preserved ejection fraction.J Am Coll Cardiol 2021;77:405-419.https://doi.org/10.1016/j.jacc.2020.11.044

2045. Kumar M, Highard K, Kranias EG, Sadayappan S. Phosphorylation of cardiac myosin-binding proteins to calcium homeostasis. J Biol Chem 2020;295:11275-1129.101.https://doi.org/10.1074/jbc.RA120.013296

205. Franssen C, Chen S, Unger A, Korkmaz Hi, De Keuenela GW,Tschope C,et al.Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:312-324. https://doi.org/10.1016/j.chpt.2015.10.007

06. Bull M, Methawin S, Strom J, Nair P, Hutchinson K, Granzier H. Alter-native splicing of retires restores diastolic function in an HFPEF-like genetic murine model(TnAAJxn). Circ Res 2016;119:764-772. https://doi.org/10.1161/CIRCRESAHA.116.308904

70. Soempdamp, Galle R, Parker S, Holewinski R, Venkatraman V, Peck K, et al.Myofilament phosphorylation in stem cell treated diastolic heart failure. Circ Res 2021:129:1125-1140.https://doi.org/10.1161/CIRCRESHAHA.119.316311

J. Weerts et al.

208. Shingu Y, Takada S, Yokota K, Shirakawa R, Yamada A, Ooka T, et al. Cor-relation between increased atrial expression of genes related to fatty acid metabolism and autophylation in patients with chronic atrial fibrillation. PLoS One 2020;15:e024713.https://doi.org/10.1371/journal.pone.0224713

209.Hahn V, Pescuici, K MS, Bedi KJc, Mari 17, Mishra, S. et al. Myocardial metabolomics of human heart failure with preserved ejection fraction. Circu-lation 2023:147:1147-1161.https://doi.org/10.1161/CIRCULATIONHA-126.01846

210. Lopaschuk GD, Karwi QG,Tian R, Wende Ar, Abel. Cardiac energy metabolism in heart failure. Crc Res 2021:128:1487-1513. https://doi.org/10.1161/CIRC-10001/10.1161/CIRCRESHA121.318214

211. Gawakoik M, Agbaedeng TA, Saljic A, Muller DN,Wilk Enchn, Schnabel R,et al. Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. Cardiovasc Res 2022:118:2415-2427. https://doi.org/10.1093/crv/cvab292

212. van Woerden G, van Veldhuisen DJ, Gorter TM, van Empvel PMM, HemataMEW,Hazebroek EJ, et al. Importance of epideradic adipose tissue localization using cardiac magnetic resonance imaging in patents with heart failure with mid-range and preserved ejection fraction. Clin Cardiol 2021:44:987-993. https://doi.org/10.1002/clc.23644

213.Gorter TM, van Woeden G, Rienstra M, Dickinson MG, Hummel YM, Voors AA,et al. Eplicard adipose tissue and invasive hemodynamics in heart failure with preserved ejection fraction.JACC Heart Fail 2020:8:667-676.https://doi.org/10.1016/j.jcf.2020.06.003

214. Pugliese NR,Paneni F,Mazzola M,De Biase N, Del Punta L,Gargani L,et al.Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail 2021;23:1858-1871.https://doi.org/10.1002/ejhf.2337

152. Conte M. Petraglia L,C. Cabaro S, Valerio V, Poggio P, Pilato E, et al. Epicardial adi-pose tissue and cardiac arrhythmias: Focus on atrial fibrillation. Front Cardiovasc Med 2022;9:932262.https://doi.org/10.3389/fcmv.2022.932262

216.Gaborib T,Veneuteck N,Cancel P.Poulle V,Gargillo P,Leprince P,et al.Human epicardial adipose tissue has a specific transcriptomic signature depending on its anatomical peri-atrial, peri-ventricular, or peri-coronlyary. Cardiovasc Res 2015;108:82-73.https://doi.org/10.1093/cvcv2008

217. Ying W, Sharma K, Yanek LR, Vaidya D, Schar M, Mark M, et al. Visceral adiposity, muscle composition, and exercise tolerance in heart failure with preserved ejection fraction. Escal Heart Foyl 2011;8:2535-2545. https://doi.org/10.1002/ehf2.13382

218.lacobcellis G,Barbaro G.Epicardial adipose tissue feeding and overfeeding the heart.Nutrition 2019;59:1-6.https://doi.org/10.1016/j.nut.2018.07.002

219.Valero-Muoz M,Li S,Wilson RM, Hulsmans M, Aprahamian T, Fuster JJ,et al.Hart failure with preserved ejection fraction induces being adipose tissue.Circ Heart Fail 2016;9:e002724.https://doi.org/10.1161/CIRCHEARTFAILURE 11.002724

220.Packer M,Lam CSP,Lund LH,Maurer MS,Borlaug BA. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: A hypothesis to explain influence of ses on the evolution and potential treatment of the disease. Eur J Heart Fail 2020;22:1551-1567. https://doi.org/10.1002/ejhf.1902

21. Marzak H, Ringlee R, Matsushita K, Marchandot B, Fitouchi S, Cardi T, et al.Impact of gender on left atrial low-voltage zones in patients with persistent atrial fibrillation: Results of a voltage-guided ablation. Front Cardiovasc Med 2023;10:1229345.https://doi.org/10.3389/fcvm.2023.1229345

22. Masuda M, Matsuda Y, Uematsu H, Sugino A, Ooka H, Kudo S, et al. Gender dif-ferences in atrial fibrosis and cardiomyopathy assessed by left atrial low-voltage areas during catheter ablation of atrial fibrillation. Am J Cardiol 2023;2037-34.https://doi.org/10.1016/j.amjcard.2023.07.001

223. Vahanian A, Beyersdor F, Fraz P, Milojevic M, Baldus S, Bauersachs J, et al.2021 ESC/EACS/GUSTelines for the management of valvular heart disease:Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology(ESC) and the European Association for Cardio-Thoracic Surgery(EACTS). Eur Heart J 2022;43:561-632. https://doi.org/10.1093/eurbearui/ehab395

224.Tamargo M,Obokata M,Reddy YNV,Pislaru SV,Lin G,Egbe AC,et al.Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction.Eur J Heart Fall 2020;22:489-498.https://doi.org/10.1002/ejhf.1699

Tan ES,Chan SP,Xu CF,Yap J, Richards AM,Ling LH,et al. Cornell product is an ECG marker of heart failure with preserved ejection fraction. Heart Asia 2019;11:011108,https://doi.org/10.1136/heartasia-2018-011108

226.Grin D, Rudolph F, Gumpfer M, Hannel J, Esner JL, Von jeines B,et al. Identifying heart failure in ECG data with artificial intelligence- a meta-analysis. Front. Front Health 2020;2:584555. https://doi.org/10.3389/fdgh

227.Unterhuber M,Rommel KP,Kresoja KP,LurzJ,Kornej,JHindricks G,et al.Deep learning detects heart failure with preserved ejection fraction using a baseline electrocardiogram.Eur Heart J Digit Health 2021;2:699-703.https://doi.org/10.1093/ehjdz/tab081

228. Kwon JM,Kim KH, Eisen HJ, Cho Y, Jeon KH, Lee SY, et al. Artificial intelligence assessment for early detection of heart failure with preserved ejection fraction based on electrocardiographic features. Eur Heart J Digit Health 2021;21:106-116.https://doi.org/10.1093/ehjdh/ztao015

229.Gill SK, Barsky A, Guan X, Bunting KV, Karwath A, Tica O, et al.; Big-Data@Hart©Consortium; cardAlc group; RATE-AF trial team. Consumer wearable devices for evaluation of heart rate control using digoxin versus beta-blockers: The RATE-AF randomized trial. Nat Med 2024;30:2030-2036.https://doi.org/10.1038/s41591-024-03094-4

30. Bunting KV, Gill S, Sitch A, Mehta S, O'Connor K, Lip GY, et al.; RAte control Therapy Evaluation in permanent Atrial Fibrillation(RATE-AF) trial group. Improving the diagnosis of heart failure in patients with atrial fib-rillation. Heart 2021:107:902-908. https://doi.org/10.1136/heartjnl-2020-318557

213.Coreyo G,Figree GA,Fletcher DF,Snelson VJ,Vernon ST, Winlaw D,et al.The health digital twin to tackle cardiovascular disease-a review of an emerging interdisciplinary field. NPJ Digit Med 2022;5:126.https://doi.org/10.1038/s41746-022-00640-7

232 Schulz C, Lemoine MD, Mearini G, Koivumaki J, Sani J, Schwedelm E, et al.PITX2 knockout induces key findings of electrical remodeling as seen in persis-tent atrial fibrillation. Circ Arrhythm Electrophysiol 2023;16:e011602. https://doi.org/10.1161/circep.122.011602

233.Torrado M,Franco D,Hernandez-Torres F,Crespo-Leiro MG,Iglesias-Gil C,Castro-Beiras A,et al.Pitx2c is reactivated in the failing myocardium and stim-ulates myf5 expression in cultured cardiomyocytes. PLoS One 2014;9:e90561.https://doi.org/10.1371/journal.pone.0090561

234. Su D, Jing S, Guan L, Li Q, Zhang H, Gao X, et al. Role of nodal-PITX2C signaling pathway in glucose-induced cardiomyocyte hypertrophy. Biochem Cell Biol 2014:92:183-190.https://doi.org/10.1139/bcb-2013-0124

表 1
P-wave parameter	Strength	Weakness
IAB	Evidence+++ for advanced IAB in advanced AtCM stages Easy to measure	Less evidence for partial IAB Moderate sensitivity
P-wave duration	Evidence ++ for early AtCM stages Easy to measure	Undersensing of low-amplitude P-wave components using standard settings Signal-to-noise ratio No established pathological cut-off Undersensing of low-amplitude P-wave
P-wave voltage	Evidence Easy to measure	Underersensing of low-amplitude P-wave
P-wave axis	Easy to measure	components using standard settings Signal-to-noise ratio
P-wave terminal force V1	Evidence ++ Easy to measure	Components using standard IAB Difficult to measure
P-wave dispersion	Evidence	Long recording ECG Difficult to measure
P-wave area	Easy to measure	Little evidence Difficult to measure
P-wave morphology in orthogonal leads	Evidence	Difficult to measure

表 2
P-wave disturbances to identify	Score
electrical arterial dysfunction and AtCM risk
Absence of any changes in P-wave parameters	0
Prolonged P-wave duration(≥120ms on	1
standard ECG or≥150ms on amplified
12-lead ECG)
Advanced inter-atrial block(P-wave≥120ms	2
plus biphasic morphology in≥2 inferior
leads) without clinical atrial arrhythmia
Advanced inter-atrial block with episodes of	3
paroxysmal atrial arrhythmia
Persistent atrial arrhythmia	4
The diagnosis of AtCM according to this consensus approach requires docu- mented electrical atrial dysfunction (AtCM P-wave score of 1 or more) in com- bination with evidence of either mechanical atrial dysfunction, atrial enlargement, or excessive atrial fibrosis. Patients at risk of AtCM P(score of 1 or deserve proactive management of comorbidity and risk factors to prevent or revert pro- gression of structural and mechanical dysfunction. A total score of 3 or more

表 3
	Echocardiography	Cardiac magnetic resonance imaging	Cardiac computed tomography
Strengths	Quick and easy to conduct with wide access Timely assessment of LA dimensions, LV/RV function, atrio-ventricular valves 3D analysis Speckle-tracking analysis	High spatial and contrast resolution Better reproducibility and lower variability Identification of LA appendage thrombus, LV/RV function, atrio-ventricular valves 3D analysis Tissue characterization(LGE,ECV,T mapping); Useful in pre-procedural planning (catheter ablation)	High spatial resolution Identification of LA appendage thrombus Presence for atrio-ventricular valves Better reproducibility and lower variability 3D analysis Possibility of feature-tracking analysis Tissue characterization(late iodine enhancement, ECV), epicardial adipose tissue characterization Useful in pre-procedural planning( catheter ablation, LA appendage
Limitations	High interobserver variability (lower for 3D analysis) Limited spatial resolution Limited by acoustic windows Tissue characterization not available	Limited availability Use of contrast medium (gadolinium) Data on normal values
Proposed thresholds of abnormality suggestive for atrial cardiomyopathy
Left atrium LA diameter (anteroposterior)	>40 mm in men >38 mm in women 91 2D:>40 ml/m2 >48 ml/m2 in women>65 years 3D:>41 ml/m2> [3D:>41 ml/m2 >48 ml/m2 in patients>65 years 80 >22 cm2 for SR patients >28 cm2 for AF patients96 LA reservoir strain 2D:<23%79,80,98	>42 mm in men >41 mm in women >60 ml/m2 3D:>78 ml/m259 $$>28cm^{292,97}$$ $$<23\%88-90$$	>45 mm in men >44 mm in women >2D:>73 ml/m2 3D:>78 ml/m259
LA area	>48 ml/m2 for AF patients96	>28 cm292,97
LA reservoir strain	2D:<23%79,80,98	<23%88-90	No studies in sufficiently large populations to propose optimal cut-offs
LA conduit strain	2D:<12% <9% in patients>65 years80	<21%99
LA booster strain	2D:<8% $8\% 88-90$
LA emptying fraction	2D:<48% $3D:<43\%$	<46% $80,94$
Right atrium RA volume indexed >36 ml/m2 in men 100 >61 ml/m2 in men >45 mm in women 94 by BSA >30 ml/m2 in women >54 ml/m2 in women 44 mm in women RA area >22 cm2101 in men >27 cm2 in men >18 cm2101 in women >24 cm2 in women 97

表 4
Evidence gaps	Future directions
Expected clinical course of the AtCM spectrum and relevant clinical markers	● More population and mechanistic studies are needed to identify the natural course of AtCM and its relation to clinically relevant outcomes.Specifically,are there features or markers that indicate a higher risk of stroke, thromboembolism or progressive HF development in individuals with or at risk of AtCM? ● How do common comorbidities(such as hypertension, obesity, diabetes mellitus and coronary artery disease) or lifestyle(smoking,obesity and exercise) as well as treatment impact the course of AtCM? ● Do women have the same trajectory for AtCM development and progression as men after accounting for biology and diagnostic/treatment biases? ● Which underlying causes lead to AtCM independent of left ventricular, right heart or valvular dysfunction? ● Secondary functional mitral or tricuspid valve regurgitation due to atrial remodelling(enlargement) may indicate progressed atrial failure, but what are important modifiable factors in this process?101,223,224
AtCM diagnostic framework is not clinically validated	● Well-powered studies are essential to improve this diagnostic framework for AtCM. ● Evaluation and refinement of the AtCM diagnostic framework in retrospective and prospective studies requires careful balancing for age, gender, cardiovascular risk factors and history of cardiac disease. ● Registry data on HF are essential to comprehensively assess AtCM/atrial failure prevalence across the ejection fraction spectrum. ● Attention is needed on the interaction and ability to distinguish between AtCM-related atrial failure and HFpEF phenotypes.
Serum biomarkers to facilitate AtCM diagnosis	● Studies exploring the role of a range of natriuretic peptides, corin, and BMP10 biomarkers in diagnosing AtCM or identifying targets for therapy, including relevant clinical cut-points. ● Explore the clinical relevance of implementing ambulatory rhythm devices, such as wearables, photoplethysmography signal processing, and implantable devices, within the AtCM framework. 225-229
Easily obtained or clinically reliable parameters to facilitate AtCM diagnosis	● The role of invasive techniques such as atrial high-density electro-anatomical mapping for the diagnosis of AtCM and prognostic stratification requires further investigation. ● Which artificial intelligence algorithms can improve the AtCM diagnostic framework and selection for future therapies? ● Reproducibility of imaging parameters is poor in the context of AF, with further data awaited on alternative approaches such as the index-beat method of acquisition following two preceding R-R intervals of similar duration.230
Uncover additional manifestations of atrial failure	● Further studies on the relationship between left atrial structural and functional alterations and AF/stroke occurrence, hard endpoints(mortality, hospitalization), as well as response to optimized medical therapy.
The role of right heart dysfunction in AtCM	● Right heart dysfunction and its impact on AtCM development requires further dedicated imaging studies.
Patient selection for future clinical trials and the threshold of AtCM markers to initiate therapy and prevent disease progression	● Identification of AtCM markers with strong prognostic value that can aid patient selection for clinical trials to improve outcomes. ● Randomized controlled trials assessing the use of anticoagulants in individuals with AtCM but without AF are needed to enhance our understanding of the impact of AtCM on stroke and thromboembolism. ● Studies on relevant atrial fibrosis cut-off values by cardiac magnetic resonance imaging to diagnose AtCM are needed. ● The digital twin approach231 could enhance (pre-)clinical research by providing a platform for studying the isolated and interconnected effects of the specific disease subsets that are relevant to the AtCM spectrum. This involves validating and translating these models for practical clinical applications, necessitating further research to seamlessly integrate theoretical frameworks into real-world healthcare practices. Examples include improved ability to distinguish anatomical versus functional factors underpinning specific P-wave disorders to redefine ECG-based risk prediction for AtCM, or to better phenotype AtCM on tissue property levels such as atrial myocardial compliance and contractility.
The effect of therapies on AtCM substrates and clinical outcomes	The potential benefit of using anticoagulant and antiarrhythmic therapy in patients with pathological P-wave parameters in the absence of atrial arrhythmias is controversial and requires further investigation. ● What kind of clinical benefit can be achieved with anti remodelling treatments(such as neprilysin or sodium-glucose co-transporter 2 inhibitors) in patients with early stages of AtCM? ● The appropriate ablation strategy in patients with AF and advanced AtCM, and its ability to modify substrate and disease progression, requires specific investigation. ● What patient outcomes are relevant for those with AtCM, what could predict atrial failure, and what is the optimal way to monitor and subsequently intervene in selected populations? ● Future research should focus on elucidating the inflammasome effect on cardiac electrophysiology mechanisms to halt or reverse and AF pathogenesis, and delineating their role in cardiomyocyte inflammatory signalling with fibroblasts and immune cells. Are selective inhibitors for these pathways effective at preventing development of AF or HF? ● Studies are needed to assess the efficacy of inhibitors in the electrical remodelling pathway, explore the regulation of atrial ion channels and calcium handling, and identify genetic predispositions to HF (for example, through PITX232-234). ● Future research should investigate the influence of epicardial adipose tissue on atrial fibrosis, sex-dependent mechanisms and the relationship with inflammation. ● Patients with AF and without AtCM who eventually develop atrial failure are of special interest to deepen the understanding of the AtCM framework.

图示：Quality of life AtCM - atrial cardiomyopathy Electrical atrial dysfunction AND Mechanical atrial dysfunction OR Atrial enlargement OR Excessive atrial fibrosis Indexed left atrial volume 40 mL/m2 Effective failure Hospitalisation, thrombo-embolism Life expectancy

图示：Healthy atria At-risk of AtCM ot potential window of opportunity to prevent AtCM and atrial failure Prolonged p-wave duration(≥120ms standard,≥150ms amplified)' Automatic rhythmia Mechanical atrial dysfunction Atrial enlargement Atrial enlargement dysfunction Atrial enlargement fibrosis Perioding p-wave duration(≥120ms standard,≥150ms amplified)' Persistent atrial arrhythmia Mechanical atrial dysfunction Atrial enlargement dysfunction Atrial enlargement fibrosis APorted ng-wave duration(≥120ms standard,≥150ms amplified)' Persistent Arrial arrhythmia APorted ng-wave fraction(≥150ms modified)' Mechanical atrial dysfunction APorted ngaveonral arrhythmia APorted ngaveonral arrhythmia APorted ngaveonral arrhythmia APorted ngaveonral arrhythmia APorted ngaveonral arrhythmia APorted ngaveonral arrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarrhythmia APorted ngaveonralarr yang's disease; and counselling against sedentary habit, obesity, smoking and alcohol abuse. ${}^{2,3}$ Potential therapeutic interventions aggressive management of risk factors $\mathcal{B}$ comorbidities ? prevent or delay ATPM development controlicIPM development controlicIPM slow progression of AF& HF of AF& HF

图示：ATRIAL ENLARGEMENT P-WAVE ABNORMALITIES 0.12 s 0.12 s P-wave duration Interatrial block STROKE ATRIAL DYSFUNCTION Amplified P-wave duration 0.15 s ATRIAL FIBROSIS Abnormal Voltage Terminal force V1 VASCULAR DEMENTIA HEART FAILURE ATRIAL FIBROSIS Abnormal spatial axis DYSSYNCHRONY Abnormal dispersion DEATH DYSSYNCHRONY

图示：A: Duration of p-wave FILTERING 2a p-wave duration Offset Offset p-wave 3a Onset Offset onset Artefactos and small electrical cardiac activity disappears 3 3b Offset Offset p-wave duration Artefactos disappear while electrical Offset activity at the end of the p-wave B: Left atrial strain 1 2a × 3c × 3c Extrapolate: LA appendageo Orfices of pulmonary veins using a pulse voltage using a pulse voltage 2 3c × 3c × 3c & 4c 5c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c × 3c Forbected: Quality of semi-automatic contouring Left atrium in apical 4-chamber view: contouring of left atrial borders for speckle tracking 3 4

图示：B: Left atrial strain 3 Extrapol: 20 LA appendage 01 orices of pulmonary veins Checking for quality of semi-automatic contouring Left atrial in apical 4-chamber view: contouring of left atrial borders for speckle tracking 3 phases of LA strain: (R) Reservoir, (C) Conduit, (B) Booster

图示：Comorbidities AtCM-atrial cardiomyopathy Healthy atria Atrial failure Abnormal geometry Abnormal wall structure Echo .LA diameter .LAVi .LA emptying fraction CMR .LA view Indirectly: .LAVi .LA area ●Diastolic dysfunction ●LAVi ●LAVi ●A wave velocity ●PA-TDI duration(TACT) ●LA mechanical ●Mitral/tricuspid dispersion .LA strain .LA flow annulus diameter .-Degree of MR/TR (LA thrombus Abnormal

引用 / 出处

2025 HFA临床共识声明：心房心肌病—从健康心房到心房衰竭. 2025.